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Parkinson's disease (PD) is a debilitating movement disorder. Growing evidence 
associates genes with familial forms of the disease. Recently, gene mutations in the FBXO7 
(PARK15) gene have been identified in patients with early-onset parkinsonism symptoms and 
pyramidal tract signs. PARK15 encodes for the E3 ubiquitin ligase FBXO7, whose function in 
the brain remains to be elucidated. In this study, I report that systemic loss of FBXO7 in mice 
results in an early-onset motor phenotype and premature death, reminiscent of the PARK15 
patients. In neuropatholgical analyses, I find a regional increase in cell death and widespread 
astrogliosis. At the molecular level, I demonstrate the binding of FBXO7 to the proteasomal 
core subunit PSMA2 and identify PSMA as non-proteolytic ubiquitination substrate. 
Interestingly, I show that loss of FBXO7 in the brain leads to reduced proteasome activity as 
a consequence of defective proteasome integrity. Taken together, I established an FBXO7-
dependent mechanism of proteasome regulation in neurons, which provides novel insight into 




1.1 Parkinson's disease (PD) 
Parkinson's disease (PD) is the second most common neurodegenerative disorder, 
which in its sporadic form affects approximately 1% of the population over the age of 60 
years. Clinically, it is characterized by motor impairment including resting tremor, 
bradykinesia, muscle rigidity and postural instability. Pathological hallmarks comprise the 
degeneration of the nigrostriatal dopaminergic system, which is thought to be causative for 
the observed motor symptoms (Sherer et al., 2012). Furthermore, post-mortem brain sections 
of PD patients show a widespread Lewy body pathology of intracellular inclusions consisting 
predominantly of the protein alpha-synuclein. The majority of the PD cases appears to be 
sporadic, but linkage studies and positional cloning have identified mutations causing 
Mendelian forms in approximately 5-10% of the cases (Cookson, 2005). Hereditary forms of 
PD resemble the sporadic form of the disease to a great extent both clinically and 
pathologically. This suggests that understanding of the associated cellular pathways is not 
only central to the understanding of the familial cases of PD but could also lead to new 
mechanistic insights and therefore therapies for sporadic PD. To date, mutations in 18 so-
called "PARK" genes or loci have been associated with PD (Table 1.1). 
 
Table 1.1: PD-associated loci and genes. 
 Gene Locus Inheritance Disease onset 
PARK1, 4 SNCA 4q22.1 dominant early onset 
PARK2 parkin 6q26 recessive early onset 
PARK3 unknown 2p13 dominant late onset 
PARK5 UCH-L1 4p13 dominant late onset 
PARK6 PINK1 1p36.12 recessive early onset 
PARK7 DJ1 1p36.23 recessive early onset 
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PARK8 LRRK2 12q12 dominant late onset 
PARK9 ATP13A2 1p36 recessive early onset 
PARK10 unknown 1p32 unclear late onset 
PARK11 GIGYF2 2q37.1 dominant late onset 
PARK12 unknown Xq21-q25 X-linked late onset 
PARK13 HtrA2 2p13.1 unclear late onset 
PARK14 PLA2G6 22q31.1 recessive early onset 
PARK15 FBXO7 22q12.3 recessive early onset 
PARK16 unknown 1q32 unclear unclear 
PARK17 VPS35 16q12 unclear unclear 
PARK18 EIF4G1 3q27 unclear unclear 
SNCA, synuclein, alpha (non A4 component of amyloid precursor); UCH-L1, ubiquitin carboxyl-terminal 
esterase L1 (ubiquitin thiolesterase); PINK1, PTEN induced putative kinase 1; LRRK2, leucine-rich 
repeat kinase 2; ATP13A2, ATPase type 13A2; GIGYF2, GRB10 interacting GYF protein 2; HtrA2, HtrA 
serine peptidase 2; PLA2G6, phospholipase A2, group VI (cytosolic, calcium-independent); FBXO7, F-
box protein 7; VPS35, VPS35 retromer complex component; EIF4G1, eukaryotic translation initiation 
factor 4 gamma, 1. 
1.1.1 Autosomal dominant forms of PD 
Alpha-synuclein (SNCA) is one example of a direct link between sporadic and 
hereditary forms of PD. It was the first PARK gene locus to be identified and found in a large 
family displaying parkinsonism with an autosomal-dominant inheritance pattern and Lewy 
body pathology (Polymeropoulos et al., 1996). Since then, two types of mutations in the 
SNCA gene have been recognized: three different point mutations (designated as PARK1) 
(Kruger et al., 1998; Polymeropoulos et al., 1997; Zarranz et al., 2004) and multiplications of 
the SCNA gene (PARK4) (Chartier-Harlin et al., 2004; Singleton et al., 2003). Although these 
mutations are rare, they led to the significant discovery that alpha-synuclein is the major 
fibrillar component of the Lewy bodies (Spillantini et al., 1997), suggesting the implication of 
altered alpha-synuclein function in both familial and sporadic PD.  
Identification of LRRK2 (Leucine-rich repeat kinase 2; PARK8) mutations provided 
another important link to sporadic PD, which on one hand is due to the close clinical 
resemblance with regard to a typical late-onset, levodopa-responsive parkinsonism 
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(Funayama et al., 2002). On the other hand, PARK8 is not only the most prevalent form of 
inherited PD but also frequently found in patients of sporadic PD itself (Bardien et al., 2011) 
and hence investigation of LRRK2 function and etiology is directly relevant for sporadic PD. 
1.1.2 Autosomal recessive forms of PD 
In contrast to dominantly inherited forms of PD, autosomal-recessive forms typically 
lead to an early onset of the disease. First identified in Japanese families with juvenile onset 
of parkinsonism (Kitada et al., 1998), mutations in the parkin gene (PARK2) are the most 
prevalent cause of early-onset PD (age of onset <40-50 years) (Periquet et al., 2003). Parkin 
patients clinically resemble sporadic PD patients but a number of additional clinical features, 
such as pyramidal signs, cerebellar features and psychiatric disease, have also been 
reported (Corti et al., 2011). Pathologically, they are characterized by a significant loss of 
dopaminergic neurons in the substantia nigra pars compacta usually with the absence of 
Lewy bodies (Mori et al., 1998). 
Growing evidence implicates the autosomal-recessive genes parkin together with 
PINK1 (PTEN-induced putative kinase 1; PARK6) as well as DJ-1 (PARK7) in mitochondrial 
regulation (Dodson and Guo, 2007). Owing to the observation that the parkinsonism-inducing 
neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is a selective inhibitor of 
mitochondrial complex I (Langston et al., 1984; Markey et al., 1984), the involvement of 
mitochondrial dysfunction has been proposed as one of the main cellular pathogenic 
mechanisms in the etiology of PD. Implication of several autosomal-recessive genes in 
mitochondrial quality control has hence confirmed the role of this organelle in PD and 
moreover uncovered this cellular system as a potential therapeutic target. 
1.1.3 Mutations on FBXO7 (PARK15) 
Autosomal-recessive mutations of FBXO7 (F-box protein 7; PARK15) were first 
reported in 2008 (Shojaee et al., 2008) and subsequently associated with hereditary 
parkinsonism in 2009 (Di Fonzo et al., 2009). Since then, mutations in the gene have been 
identified in several families (Table 1.2). PARK15 patients display a juvenile onset of the 
disease with a broad spectrum of symptoms. While most of the so far reported cases show a 
parkinsonian-pyramidal syndrome (PPS), the phenotypes range from only pyramidal 
involvement (Shojaee et al., 2008) over a mixed contribution as parkinsonian-pyramidal 
syndrome (PPS) (Di Fonzo et al., 2009) to only parkinsonism (which also includes also a 
broad spectrum of disorders) (Lohmann et al., 2015). All patients treated with the amino acid 
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precursor of dopamine, levodopa, display a rather short-term response, however, with strong 
dyskinetic and behavioral side-effects. Other symptoms include dystonia, dysphagia, 
dysarthria, upgaze limitation, incontinence, cortical atrophy and cognitive decline (Di Fonzo et 
al., 2009; Lohmann et al., 2015). FBXO7 mutations were found to be mainly homozygous 
missense alterations with only two exceptions, one heterozygous missense (Lin et al., 2013) 
and one compound heterozygous mutation paired with a splice site variation (Di Fonzo et al., 
2009). While the clinical phenotypes of the identified PARK15 patients are well described, 
data on underlying pathological mechanisms is still missing. 
 
Table 1.2: Clinical characteristics of PARK15 patients. 







(Di Fonzo et 
al., 2009) 





Cakmakli et al., 
2014) 
Familiy origin Iran Italy Netherlands Pakistan Turkey 
Age of onset, 
y 
30s 10 18 17 14 













+ + + - 
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+ (1 patient 
treated) 
















B, bradykinesia; R, rigidity; RT, resting tremor; PI, postural instability 
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1.2 Parkinson's disease and the ubiquitin-proteasome system (UPS) 
FBXO7 encodes a protein that functions as an E3 ubiquitin ligase and is hence part of 
the cell's main protein degradation pathway, the ubiquitin-proteasome system (UPS). 
Different lines of research have implicated dysfunction of the UPS or its components in the 
etiology of PD. First hints for this link derived from the observation of inclusion bodies that are 
ubiquitin-positive. Further research linked several components of the UPS machinery itself to 
PD. 
1.2.1 Proteasomal dysfunction 
Lewy bodies are protein inclusions and a major pathological hallmark of sporadic PD. 
The presence of ubiquitin, among other proteins, in the inclusion bodies suggested an 
involvement of dysfunctional proteasomal clearance mechanisms (Lowe et al., 1988). Indeed, 
postmortem tissue analyses of PD patients showed a reduction of proteasome activity in the 
substantia nigra (Furukawa et al., 2002; McNaught et al., 2003), but an increase of activity in 
other brain regions, such as the cerebral cortex and the striatum (Furukawa et al., 2002), 
possibly as a compensatory mechanism. The association of reduced proteasome function 
and pathogenesis of PD was further supported by in vitro studies demonstrating that 
proteasome inhibition led to degeneration of primary dopaminergic neurons with alpha-
synuclein and ubiquitin-positive inclusion body formation (Rideout et al., 2005). Moreover, 
systemic administration as well as nigral stereotactic injection of proteasome inhibitors in rats 
was reported to induce a behavioral and pathological phenotype resembling PD (McNaught 
et al., 2002a). However, these findings remain controversial due to a lack of reproducibility 
(Bove et al., 2006; Hawlitschka et al., 2007; Kordower et al., 2006), and hence in vivo 
administration of proteasome inhibitors is not considered to be a valid approach to model PD. 
A more recent study used a genetic approach to delete a subunit of the 26S proteasome in a 
brain region-specific manner. The mouse model showed Lewy body-like inclusions and 
neurodegeneration in the targeted nigrostriatal pathway or forebrain, demonstrating that 
proteasome dysfunction is a factor that can directly trigger the pathogenesis of 
neurodegenerative disease involving protein aggregates and neuronal death (Bedford et al., 
2008).  
The central position of the proteasome in the cell's functional network and its 
sensitivity to internal and external stimuli (Demasi et al., 2003; Wang et al., 2010), however, 
make it difficult to distinguish dysfunctions of the proteasome as a cause or a consequence. 
This, e.g., holds true for the alpha-synuclein-containing aggregates. While the proteinaceous 
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inclusions are ubiquitin-positive and point to deficient proteasomal degradation, it was also 
reported that wild type or mutant alpha-synuclein as well as alpha-synuclein aggregates in 
turn impair proteasome activity (Bodner et al., 2006; Fujita et al., 2007; Sun et al., 2005). 
Further research is hence required to shed light on the mechanisms of proteasome function 
and regulation in the early phases of disease pathogenesis. 
1.2.2 Ubiquitin proteasome system components associated with Parkinson's disease 
Genetic evidence underscoring the role of UPS components in PD is supported by at 
least two genes which are part of the pathway of ubiquitin-dependent degradation of proteins 
and are associated with familial cases of the disease.  
Parkin (PARK2) encodes an E3 ubiquitin ligase that attaches ubiquitin to a multitude 
of substrate proteins. Upon mitochondrial stress, parkin translocates to the outer 
mitochondrial membrane (Narendra et al., 2008) where it ubiquitinates several substrate 
proteins, ultimately leading to the removal of defective mitochondria (Tanaka et al., 2010). 
Some of the mitochondrial ubiquitination targets of parkin are degraded by the proteasome, 
such as the mitofusins (Chan et al., 2011) which are mitochondrial fusion regulators. 
Furthermore, parkin is viewed as a protective protein as overexpression can rescue cells from 
stress-induced unfolded protein response (Imai et al., 2000) or protect against proteasomal 
dysfunction and toxicity induced by alpha-synuclein (Petrucelli et al., 2002; Yang et al., 2003). 
This suggests that loss of functional parkin and its E3 ligase activity can lead to pathological 
alterations. 
Another UPS-component that was linked to genetic PD is ubiquitin carboxy-terminal 
hydrolase 1 (UCH-L1, PARK5) encoding a deubiquitinating enzyme. UCH-L1 is a highly 
abundant enzyme making up 1-2 % of the brain protein content (Solano et al., 2000; 
Wilkinson et al., 1992; Wilkinson et al., 1989). Mutations in UCH-L1 were reported to lead to 
an in vitro reduction of its deubiquitinase activity (Nishikawa et al., 2003) and shown to result 
in reduced intracellular ubiquitin levels (Osaka et al., 2003) which could potentially lead to a 
flawed clearance of proteins. Interestingly, inhibition of UCH-L1 in cell cultures of rat ventral 
midbrain neurons was shown to cause formation of inclusions and dopaminergic neuron 
degeneration (McNaught et al., 2002b). Taken together, dysfunction of the proteasome and 
components of the ubiquitin-attachment pathway have implicated the UPS as another integral 




1.3 Ubiquitin Proteasome System
The ubiquitin proteasome system 
pathways of the cell. It is therefore involved in virtually every cellular process requiring the 
precise spatial and temporal regulation of protein levels. The signal for a protein to be 
degraded is the posttranslational modification with the highly conserved, 
ubiquitin (Ub). Protein ubiquitination is an enzymatic reaction and involves three steps. In the 
first step, Ub is activated in an ATP
E1 ubiquitin-activating enzyme (E1). Next, ubiquitin is transferred to th
conjugating enzyme (E2). Finally, the E3 ubiquitin ligase (E3) mediates the transfer of Ub 
from the E2-Ub conjugate to the substrate protein (
occurs on a lysine residue of the substrate protein 
Polyubiquitin chains are formed by attachment of another Ub molecule to one of the seven 
lysine (K) residues of the prec
accepted signal for degradation of a pr
1998).  
Figure 1.1: The ubiquitin proteasome system
dependent manner and facilitates the transfer to the E2 
the E2-Ub conjugate as well as the substrate protein to facilitate ubiquitin attachment on the substrate. 
Ubiquitinated proteins are then either destined for proteasomal degradation or altered in their protei
1.3 Ubiquitin Proteasome 
 
(UPS) is one of the cell's major protein degradation 
-dependent manner and thereby covalently bound to the 
Figure 1.1). Ubiquitin attachment typically 
as a single moiety or polymeric Ub chains. 
eding Ub. K48-linked polyubiquitin chains are the widely 
otein by the proteasome (Hershko and Ciechanover, 
 (UPS). The E1 enzyme activates ubiquitin (Ub) in an ATP










1.3.1 The 26S proteasome 
The 26S proteasome is a 2.5 MDa macromolecular complex responsible for the ATP
dependent degradation of polyubiquitinated proteins. It consists of the proteolytic 20S core 
particle (CP) and one or two 19S regulatory par
barrel-shaped particle comprising of four stacked rings with seven subunits each (α1
/ β1-7 / α1-7) (Coux et al., 1996
activity and account for the caspase
respectively (Kisselev et al., 1999
sites for the RP and restrict the access to the proteolytic chamber via their N
(Groll et al., 2000). For the targeted degradation of polyubiquitinated proteins, CPs need to be
associated with the RP. The RP consists of 19 different subunits and is responsible for 
recognition of the ubiquitinated substrate, removal of its ubiquitin chain by deubiquitinases 
and subsequent unfolding and translocation of the substrate polypeptide c
(Tomko and Hochstrasser, 2013
Figure 1.2: Different assembly forms of the 
rings of α and β subunits. One or two 19S regulatory particles, together with the 20S core particle compose 
the degradation-competent 26S or 30S proteasome holoenzyme.
 
1.3.2 E3 ligases 
In contrast to K48-
proteasomal targeting, K63 chaintypes have been mainly associated with modification of 
protein function. The biological contexts in which the other chaintypes, namely K6, K11, K27, 
1.3 Ubiquitin Proteasome 
ticles (RP) (Figure 1.2). The CP is a hollow 
). Three of the seven β-subunits (β1, β2, β5) harbor proteolytic 
-, trypsin- and chymotrypsin-like protease activities, 
; Seemuller et al., 1995). The outer α-rings serve as contact 
hain into the core 
).  
 
proteasome. The 20S core particle consists of four heptameric 
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K29 and K33, are involved have not yet been investigated in great detail (Ikeda and Dikic, 
2008). While examples of E2 enzymes that possess an internal preference for assembly of a 
specific chaintype have been reported (Chen and Pickart, 1990; Petroski and Deshaies, 
2005), a recent study suggests that it is also the E3 ligase itself, which instructs a given E2 to 
generate a specific chaintype (David et al., 2011). The crucial role of E3 ligases is also 
reflected in their large number with more than 600 ligases encoded in the human genome. In 
contrast, only 30 E2 and two E1 enzymes are known to date (Scheffner et al., 1995). 
Interestingly, one E3 ligase can ubiquitinate more than one substrate and a given substrate in 
turn, can be targeted by more than one E3 ligase. This further increases the level of 
complexity with which cellular proteins and hence pathways can be regulated in response to 
external and internal stimuli.  
Based on their mechanism of ubiquitin-attachment, E3 ligases can be classified into 
two main families: HECT-type and the RING-type E3 ubiquitin ligases. HECT (homologous to 
E6AP C-terminus) ligases recruit the E2-Ub conjugate and transiently form a thioester with 
the ubiquitin, prior to catalyzing its attachment to the substrate (Pickart and Eddins, 2004). 
RING (Really Interesting New Gene) ligases in contrast act as a scaffold that facilitates the 
ubiquitin transfer from the E2 enzyme to the substrate by bringing both into spatial proximity 
(Pickart and Eddins, 2004). RING E3 ligases exist as monomers or as multimeric complexes. 
FBXO7 (PARK15), for example, is part of a multimeric E3 ligase complex, the so-called SCF-
complex. 
1.3.3 SKP1-cullin1-F-box protein (SCF) complex 
SCF-type multisubunit E3 ligases were first identified in yeast (Feldman et al., 1997; 
Skowyra et al., 1997) and were initially implicated in the cell cycle. The two main functions of 
an E3 ligase - E2-Ub recruitment and substrate binding - are performed by different subunits 
of the complex (Figure 1.3). Cullin1 (Cul1) acts as the scaffold protein and binds to the 
RING-box protein 1 (Rbx1), which recruits the E2-Ub conjugate. The small adaptor protein S-
phase kinase-associated protein 1 (SKP1) binds to the F-box protein (FBP) (Cardozo and 
Pagano, 2004). FBPs are responsible for the critical step of substrate-recognition and 
recruitment to the complex. While SKP1, Cul1 and Rbx1 represent the ligase core, the FBP is 
the interchangeable subunit, enabling the SCF E3 ligase to rapidly adapt to the cell's needs 
by ubiquitinating different subsets of proteins at a time. All 68 members of the mammalian 
FBP family contain the name-giving F-box domain, an approximately 40 amino acid long 
stretch, which enables the FBP to form the SCF complex. Based on other structural motifs 
 
FBPs have been further categorized into FBXLs, FBXWs and FBXOs. FBXLs contain leucin
rich repeats while FBXWs contain WD40 domains and FBXOs 
structural motifs (Jin et al., 2004
Despite the large number of identified FBPs, studies on their individual biological 
functions are sparse. Recent data implicate
and neurodegenerative disease. FBXW8 and FBXO31, e.g., were shown to govern cerebellar 
development by regulating dendrite and axon growth, respectively 
Vadhvani et al., 2013). FBXO2 on the other hand was reported to be involved in regulation of 
the amyloid precursor protein either indirectly by targeting β
the amyloid precursor protein itself for degradation 
Since the discovery of autosomal
gaining increasing attention (Shojaee et al., 2008
Figure 1.3: The SKP1-cullin1-F-
which consists of the core components cullin
SKP1 and cullin-1 facilitate the binding of F
 
1.4 FBXO7 protein function
The first studies implicated 
ubiquitination substrates HURP (hepatoma up
cIAP1 (cellular inhibitor of apoptosis 1) and TRAF2 (TNF receptor
et al., 2006; Kuiken et al., 2012
D/cdk6 interaction, leading to an increase in cdk6 activity and suggesting that 
potential oncogene (Laman, 2006
negatively regulate the proliferation and differentiation of hematopoietic progenitor cells 
(Lomonosov et al., 2011) and that reduced 
model led to anemia (Randle et al., 2015
1.3 Ubiquitin Proteasome 
comprise "other" or no typical 
). 
 several FBPs in the context of neurodevelopment 
(Litterman et al., 2011
-secretase or directly by targeting 
(Atkin et al., 2014; Gong et al., 2010
-recessive mutations in familial cases of PD, FBXO7 is 
). 
 
box protein (SCF) complex. The SCF complex is a multimeric E3 ligase, 
-1, SKP1 and Rbx1. While Rbx1 recruits the E2
-box proteins which in turn recruit the substrate. 
 
FBXO7 in cell cycle regulation via its reported 
-regulated protein) (Hsu et al., 2004
-associated factor2) 
). FBXO7 was furthermore reported to facilitate the cyclin 
). Along the same line of research, FBXO7 was shown to 









) as well as 
(Chang 
FBXO7 is a 
Introduction 
1.4 FBXO7 protein function 
11 
 
While involvement of FBXO7 in cell cycle regulation is interesting, it does not account 
for its anticipated role in postmitotic neurons given that FBXO7 mutation lead to familial forms 
of PD, a neurodegenerative disease. Examination of PARK15 patient skin fibroblasts 
uncovered that two of the so far identified point mutations leads to a loss of protein stability as 
most of the main FBXO7 protein isoform 1 was depleted (Zhao et al., 2011). Two interesting 
lines of research imply FBXO7 in regulation of the mitochondrial and proteasomal systems. 
FBXO7 was shown to interact with PINK1 and Parkin, which are both involved in 
mitochondrial quality control. Consequently, reduced expression of FBXO7 in SH-SY5Y cells 
lead to faulty translocation of parkin to mitochondria, a key step in mitophagy (Burchell et al., 
2013). The evidence connecting FBXO7 to the proteasomal system has so far been more 
indirect. FBXO7 harbors a ubiquitin-like (Ubl) domain at its N-terminus, which is commonly 
found in proteins that regulate proteasomal function (Hartmann-Petersen and Gordon, 2004). 
Additionally, it was shown to dimerize with the proteasomal inhibitor 31 (PI31) via a globular 
domain of 150 amino acids that is structurally quite similar and has hence been termed FP 
(FBXO7-PI31) domain (Kirk et al., 2008). While studies in Drosophila associate nutcracker, 
an orthologue of FBXO7 with low sequence similarity, with DmPI31 in the control of 
proteasome activity (Bader et al., 2011), FBXO7's function in the control of mammalian 
proteasome activity still remains elusive. 
 
1.5 Aim of the Study 
Mutations in the FBXO7 (PARK15) gene are associated with familial PD. While the 
patients present with a complex spectrum of motor deficits, their neuropathology remains 
elusive. Also, it remains unclear how the mutations affect protein function. Owing to a report 
on loss of FBXO7 expression in skin fibroblasts isolated from PARK15 patients, I took a loss-
of-function genetics approach. I investigated the systemic loss of FBXO7 in a mouse model 
and characterized its neuropathological features. In addition, I examined the function of 
FBXO7 by screening for and establishing novel interaction partners and potential 




2.1 Generation of a FBXO7 knockout mouse 
To gain further insights into FBXO7's function in the brain, we generated a FBXO7 
conventional knockout mouse using ES cells purchased from the International Knockout 
Mouse Consortium. Exon 4 of the FBXO7 gene is flanked by FLP-recognition target (FRT) 
and loxP sites, a lacZ reporter cassette and a neomycin selection cassette (Figure 2.1 a). 
After successful breeding with the Ella-Cre driver line, exon 4 and the neomycin selection 
cassette were excised leading to the expression of truncated FBXO7 and β-Galactosidase (β-
Gal) proteins driven by the endogenous FBXO7 promoter and terminated by a 
polyadenylation (pA) signal. Subsequently, successful disruption of the FBXO7 gene was 
confirmed by a genotyping PCR (Figure 2.1 b, kindly provided by Siv Vingill). I furthermore 
validated the successful generation of the FBXO7 knockout mouse at the protein level by 
immunoblotting of different brain tissues with the FBXO7 and β-Gal antibodies. As expected, 
FBXO7+/- mice showed reduced and FBXO7-/- mice a complete loss of FBXO7 protein levels 
(Figure 2.1 c). This result also validated the specificity of the FBXO7 antibody used in this 
study. Vice versa, β-Gal expression was absent from FBXO7+/+ mice and showed half the 
dose in FBXO7+/- as compared to FBXO7-/- mice (Figure 2.1 d).  
At postnatal day (P) 18, FBXO7-/- mice displayed reduced body size (Figure 2.1 e). 
Even though FBXO7-/- mice were born at the expected Mendelian ratios, both genders of 
knockout mice did not live beyond the third postnatal week (Data Siv Vingill). Basic behavioral 
testing and general examination of the mice performed by Siv Vingill showed that FBXO7-/- 
mice displayed kyphosis and mild hind limb clasping. Due to their reduced body size, physical 
weakness and motor deficits, FBXO7-/- mice were not examinable with the rotarod paradigm 
or other more demanding motor tests. Deletion of one FBXO7 allele, however, did not result 
in haploinsufficiency since FBXO7+/- mice displayed normal body weight and motor 
performance during a 12 months examination period. Altogether, our results suggest that 
complete loss of FBXO7 in the mouse model system leads to a rapid decline of physical 
health state as well as early-onset motor symptoms.  
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Figure 2.1: Validation of the FBXO7 knockout mouse: (a) Schematic representation of the mutated allele, 
in which exon 4 of the FBXO7 gene is flanked by loxP sites. The transgenic construct comprises FRT sites, a 
splice acceptor site (En2-SA), a lacZ reporter cassette as well as a β-actin:neomycin selection cassette. (b) 
Representative image of a genotyping PCR of FBXO7+/+, FBXO7+/- and FBXO7-/- mice using primers 
designed around exon 4 to test for presence or absence of the FBXO7 gene or the β-Gal reporter cassette, 
respectively. Image was kindly provided by Siv Vingill. (c) P18 midbrain lysates of FBXO7+/+, FBXO7+/- and 
FBXO7-/- mice were subjected to immunoblotting with the FBXO7 and 14-3-3 antibodies. The latter served as 
a loading control. (d) P18 cortical lysates of FBXO7+/+, FBXO7+/- and FBXO7-/- mice were subjected to 
immunoblotting with the β-Galactosidase and 14-3-3 antibodies. The latter served as a loading control. (e) 
Picture of P18 FBXO7+/+, FBXO7+/- and FBXO7-/- mice. 
 
2.2 FBXO7 is abundantly expressed in the mouse brain and 
localizes to the cytoplasm in neurons 
In order to investigate the spatial distribution of FBXO7 in the mouse brain, I took 
advantage of the lacZ expression cassette driven by the endogenous FBXO7 promoter. For 
this, I subjected sagittal brain sections of P18 FBXO7+/+ and FBXO7-/- mice to lacZ staining. 
While there was no staining detectable in the FBXO7+/+ brain (Figure 2.2 f), I found 
abundant  β-Gal expression in the FBXO7-/- brain (Figure 2.2 a, d) including the cortex, 
hippocampus, thalamus, midbrain regions and brainstem. In the cortex, the signal was more 
prominent in the deeper layers, while the hippocampus displayed a strong signal throughout 
its major regions (Figure 2.2 b, c). A higher magnification of the cerebellar layers revealed β-
Gal expression in the Purkinje cell layer (PCL) and very low expression in the cerebellar 
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granule neurons of the internal granular layer (IGL) with a few stained cells presumably 
representing interneurons (Figure 2.2 e). Interestingly, FBXO7 expression was not only 
restricted to neurons but could be abundantly observed in the white matter tracts of the 
striatum, the corpus callosum and the white matter region of the cerebellum indicating the 
expression of FBXO7 in oligodendrocytes in the CNS (Figure 2.2 a, b, e). Collectively, these 
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Figure 2.2: FBXO7 expression in the murine brain: (a, b) 40 μm thick sagittal sections at lateral 0.36 mm 
and 2.04 mm, respectively, of FBXO7-/- mice were subjected to lacZ staining. Cb= cerebellum, cc= corpus 
callosum, Ctx= cortex, Hpc= hippocampus, M= medulla oblongata, Olf= olfactory bulb, Pn= pontine nucleus, 
Th= thalamus, Sc= superior colliculus, Str= striatum. Scale bars equal 1000 μm. (c) Inset represents a higher 
magnification picture of (a) showing the cortical layers I-VI and the cc. Scale bars equal 200 μm. (d) Inset 
represents a higher magnification picture of (a) showing the hippocampal formation. CA1-3= cornu ammonis 
1-3, DG= dentate gyrus. Scale bar equals 200 μm. (e) Inset represents a higher magnification picture of (b) 
showing the cerebellum. PCL= Purkinje cell layer, IGL= internal granular layer, WM= white matter. Scale bar 
equals 200 μm. (f) 40 μm thick sagittal section of a FBXO7 +/+ mouse subjected to lacZ staining serving as a 
negative control with no β-Galactosidase reactivity. Scale bar equals 1000 μm. 
 
Having established the expression of FBXO7 in the mouse brain, I investigated the 
subcellular localization in neurons by first carrying out a crude subcellular fractionation 
analysis. Immunoblotting using the FBXO7 antibody revealed that FBXO7 robustly localized 
to the cytoplasmic fraction and was absent from the nuclear fraction in P18 mouse cortical 
tissue (Figure 2.3 a). Furthermore, due to the lack of a specific antibody for detection of 
endogenous FBXO7 by immunocytochemistry, I resorted to transfection of rat cultured 
hippocampal neurons with a GFP-tagged FBXO7 plasmid. GFP-FBXO7 localized to the 
cytoplasm as well as the neurites but not to the nucleus, further confirming FBXO7 as a 
cytotplasmic protein in neurons (Figure 2.3 b). 
 
Figure 2.3: FBXO7 localizes to the cytoplasm in neurons: (a) Cortical lysates of P18 FBXO7+/+, 
FBXO7+/- and FBXO7-/- mice were subjected to subcellular fractionation, followed by immunoblotting with the 
FBXO7 antibody. 14-3-3 and SP1 served as cytoplasmic and nuclear marker, respectively. (b) Fluorescent 
microscopy pictures of cultured hippocampal neurons transfected with GFP-FBXO7 expressing plasmid, 
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2.3 No α-synuclein- or amyloid precursor protein (APP)-positive 
inclusions in the brain of FBXO7-/- mice 
Ubiquitin- and α-synuclein-positive inclusions are hallmarks of sporadic PD but their 
prevalence in genetic cases of the disease and the reproducibilty in PD mouse models are 
variable (Hirsch, 2007; Poulopoulos et al., 2012). To find out whether the FBXO7-/- mouse 
displays any α-synuclein abnormalities in the brain, I subjected sagittal brain sections of P18 
FBXO7+/+ and FBXO7-/- mice to immunohistochemistry using the α-synuclein antibody. 
Screening of the FBXO7-/- mouse brain sections revealed no α-synuclein-positive inclusions 
(Figure 2.4 a). Additionally, I checked α-synuclein protein levels in P18 mouse cortical 
lysates and found no change (Figure 2.4 b, c). Owing to FBXO7's expression in 
oligodendrocytes, I wondered whether the axonal integrity on a lightmicroscopical level was 
intact. To test this, I subjected sagittal brain sections of P18 FBXO7+/+ and FBXO7-/- mice to 
immunohistochemistry using the APP antibody as APP is prone to accumulate as a result of 
axonal damage (Trapp et al., 1998). Screening of the white matter regions of the corpus 
callosum and the cerebellar white matter revealed no APP-positive inclusions (Figure 2.4 d). 
Also, APP protein levels in P18 FBXO7-/- mouse cortical lysates were unaltered when 
compared to the wild type littermates (Figure 2.4 e, f).  
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Figure 2.4: FBXO7-/- mouse brains display no α-synuclein- or APP-positive inclusions: (a) 
Representative images from 5 μm thick sagittal paraffin-embedded brain sections of the cortical region of P18 
FBXO7+/+ and FBXO7-/- mice. Whole brain sections were subjected to immunohistochemistry using the α-
synuclein antibody and screened for inclusions. Scale bar equals 40 μm. (b) Cortical lysates of P18 
FBXO7+/+ and FBXO7-/- mice were subjected to immunoblotting using the α-synuclein and γ-tubulin 
antibodies. The latter served as a loading control. (c) Densitrometric quantification of α-synuclein protein 
levels in (b). n= 5 FBXO7 litterpairs were analyzed (Paired t-test, ns= non significant, mean + s.e.m.). (d) 
Representative images from 5 μm thick sagittal paraffin-embedded brain sections of the corpus callosum and 
cerebellar white matter region of P18 FBXO7+/+ and FBXO7-/- mice. Whole brain sections were subjected to 
immunohistochemistry using the APP antibody and screened for inclusions. Scale bar equals 40 μm. (e) 
Cortical lysates of P18 FBXO7 +/+ and FBXO7 -/- mice were subjected to immunoblotting using the APP and 
γ-tubulin antibodies. The latter served as a loading control. (f) Densitrometric quantification of APP protein 
levels in (e). n= 8 FBXO7 litterpairs were analyzed (Paired t-test, ns= non significant, mean + s.e.m.). 
 
2.4 Increased astrogliosis and elevated levels of apoptosis in the 
brain of FBXO7-/- mice  
Increased inflammation is associated with several neurodegenerative diseases, 
including Parkinson's disease (Damier et al., 1993; Dickson, 2012). I hence compared sagittal 
brain sections of P18 FBXO7+/+ and FBXO7-/- mice first for astrogliosis using the glial 
fibrillary acidic protein (GFAP) antibody. Indeed, GFAP levels were increased in the FBXO7-/- 
animals (Figure 2.5 a, b). I also examined for increased microgliosis using the Iba1 antibody 
on the same brain sections but found no difference (Figure 2.5 c, d, e).  
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Figure 2.5: FBXO7-/- mice show increased levels of astrogliosis in the brain: (a) Representative images 
from 5 μm thick sagittal paraffin-embedded brain sections of the cortical region of P18 FBXO7+/+ and FBXO7-
/- mice. Whole brain sections were subjected to immunohistochemistry using the GFAP antibody. Scale bar 
equals 40 μm. (b) Quantification of GFAP-positive area (% stained area/mm²) in the cortex of at least three 
independent FBXO7+/+ and FBXO7-/- littermates. Three anatomically matched sections per animal were 
quantified in a blinded manner and analyzed using a custom-designed macro. (Paired t-test, *p<0.05, mean + 
s.e.m.). (c) Representative images from 5 μm thick sagittal paraffin-embedded brain sections of the cortical 
region of P18 FBXO7 +/+ and FBXO7 -/- mice. Whole brain sections were subjected to immunohistochemistry 
using the Iba1 antibody. Scale bar equals 40 μm. (d) Quantification of Iba1-positive area (% stained 
area/mm²) in the cortex of at least three independent FBXO7 +/+ and FBXO7 -/- littermates. Three 
anatomically matched sections per animal were quantified in a blinded manner and analyzed using a custom-
designed macro. (Paired t-test, ns= non significant, mean + s.e.m.). (e) Quantification of Iba1-positive cells 
(cells/mm²) of the same brain sections quantified in (d). Quantification was done manually and in a blinded 
manner. (Paired t-test, ns= non significant, mean + s.e.m.). 
 
Cell death and apoptosis are major factors in neurodegenerative diseases and are 
usually accompanied by inflammation (Wyss-Coray and Mucke, 2002). I hence determined, 
whether brain sections of P18 FBXO7+/+ and FBXO7-/- mice showed any abnomality in cell 
death levels using a commercial TUNEL kit. The TUNEL kit detects sites of fragmented DNA 
that result from apoptotic pathways. Interestingly, many of the brain regions analyzed (cortex, 
cerebellum, hippocampus) showed a tendency to elevated levels of apoptotic cells being only 
in the cortex significantly increased (Figure 2.6 a, b). Levels of apoptotic cells in the mibrain 
(Figure 2.6 c, d) as well as the number of dopaminergic in the substantia nigra were 
unchanged (Data Siv Vingill).  
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Figure 2.6: FBXO7-/- mice display increased apoptosis in the brain: (a) Representative images from 5 μm 
thick sagittal paraffin-embedded brain sections of the cortical, cerebellar and hippocampal region of P18 
FBXO7+/+ and FBXO7-/- mice. Whole brain sections were subjected to immunohistochemistry using a 
TUNEL detection kit, staining apoptotic cells. Arrowheads indicate apoptotic cell bodies. Scale bar equals 40 
μm. (b) Quantification of TUNEL-positive cells (cells/mm²) in the cortex, cerebellum and hippocampus. Three 
anatomically matched sections per animal were quantified manually in a blinded manner. (Paired t-test, 
*p<0.05, ns= non significant, mean + s.e.m.). (c) Representative images from 5 μm thick coronal paraffin-
embedded brain sections of the midbrain region of P18 FBXO7+/+ and FBXO7-/- mice. Whole brain sections 
were subjected to immunohistochemistry using a TUNEL detection kit, staining apoptotic cells. Arrowheads 
indicate apoptotic cell bodies. Scale bar equals 40 μm. (d) Quantification of TUNEL-positive cells (cells/mm²) 
in the midbrain. Three anatomically matched sections per animal were quantified manually in a blinded 
manner. (Paired t-test, ns= non significant, mean + s.e.m.). 
 
To corroborate the increased levels of apoptosis observed in vivo, I performed a 
survival assay by acutely knocking down FBXO7 in cultured cortical neurons. For this, I 
transfected cortical neurons at day in vitro (DIV) 3 with plasmids encoding either the control 
vector, functional FBXO7 shRNA or non-functional shRNA (Figure 2.7 b) and quantified the 
number of pyknotic nuclei and level of cleaved caspase 3 at DIV 7. The number of apoptotic 
neurons was increased by more than 2.5 fold in the condition, in which FBXO7 was knocked 
down as compared to control cells (Figure 2.7 a), suggesting that FBXO7 is essential for 
cortical neuron survival both in vivo and in vitro. 
 
Figure 2.7: FBXO7 is required for neuronal survival: (a) Apoptotic cortical neurons were counted manually 
in a blind manner and quantified. At least four independent experiments were included in the analysis 
(ANOVA, **p<0.01, mean + s.e.m.). (b) Lysates from cultured rat cortical neurons were nucleofected at DIV0 
with either control pSuper, functional FBXO7 shRNA or non-functional FBXO7 as an additional control. 
Neurons were harvested four days after nucleofection and subjected to immunoblotting with the FBXO7 and 
14-3-3 antibodies. The latter served as a loading control. 
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2.5 Screening for novel FBXO7 interacting proteins 
Since the first reports associated mutations in the FBXO7 gene with hereditary 
parkinsonism, FBXO7 has been implicated in several cell contexts including cell cycle, 
mitophagy and the proteasome (Nelson et al., 2013). However, mechanistic insight into how 
FBXO7 influences these cell functions is very limited and in particular its role as an E3 ligase 
remains greatly underexplored.  
Ubiquitination targets have to directly interact with the E3 ligase. To uncover those, I 
sought to identify interaction partners of FBXO7. For this, I carried out a yeast two-hybrid 
screen using full-length FBXO7 fused to the DNA-binding domain (DNA-BD) and a human 
fetal brain cDNA library fused to the activator domain (AD) of the yeast transcription factor 
Gal4. Both the FBXO7 plasmid and the plasmid library were transformed into different yeast 
strains, the yeast strains were mated and subsequently selected for compensation of 
auxotrophy by growth on triple amino acid-lacking medium plates. The selection was based 
on two amino acid synthesis genes being encoded on either the bait or the prey plasmid. The 
third selection gene was transactivated by physical proximity of the Gal4 transcription factor 
DNA-BD and AD upon interaction of FBXO7 with one of the library proteins.  
The initial control tests of the yeast two-hybrid screen included investigation of bait 
toxicity, bait autoactivation and control mating. Normal yeast colony growth of the 
tryptophane-auxotrophic yeast AH109 transformed with pGBT9-BD-FBXO7 on SD/-Trp plates 
showed that no bait toxicity was present. To exclude that the bait construct transactivates the 
third selection gene without the prey construct, yeast growth of pGBT9-BD-FBXO7 
transformed into AH109 yeast on SD/-His plates was tested and resulted in no colony growth. 
The control mating between the transformed AH109 and Y187 yeast strains yielded stable 
growth on SD/-Trp/-Leu indicating that yeast mating had taken place.  
After successful small-scale control mating, the large-scale mating for library 
screening was carried out by growth selection of the transformed yeast strains on SD/-Trp/-
Leu/-His plates. Subsequently, library titer, diploid number and mating efficiency were 
determined as verification factors for the screen. The library titer was determined to be 1.24 x 
108 and was in the range of expected values (>2 x 107 cells). The diploid number counts 
indicated that a total of 14.6 x 106 clones were screened, which is well above the 
recommended 1 x 106 for efficient screening. Mating efficiency was determined by the ratio of 
viability of diploids to the viability of the prey library and was found to be 12.3 %, which was 
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exceeding the expected 2 - 5 %. The verification factors indicated that the screen was 
efficiently carried out.  
Approximately 175 yeast colonies grown on the triple selection plates were then 
subjected to a ß-galactosidase assay to exclude false-positives followed by colony PCR and 
sequencing for identification of the putative interactor. Among the identified interaction 
partners were already published interactors, such as PI31 (Kirk et al., 2008) and SKP1 (Hsu 
et al., 2004) (Table 2.1). Interestingly, two novel putative interactors were identified - the 
proteasomal subunit alpha 2 (PSMA2) and the light chain of the microtubule-associated 
protein 1 B (MAP1B-LC1) (Table 2.1).  
 
Table 2.1: List of identified interaction partners by yeast two-hybrid screening. 
Putative interactor Number of hits Status 
PI31 34 Known interactor (Kirk et al., 2008) 
SKP1 1 Known interactor (Hsu et al., 2004) 
PSMA2 13 Unknown interactor 
MAP1B-LC1 2 Unknown interactor 
 
2.6 FBXO7 interacts with members of the MAP1 (microtubule-
associated protein) familiy 
MAP1A, MAP1B and MAP1S are microtubule-associated proteins. While MAP1S is a 
comparably small (120 kDa) protein with ubiquitous expression (Liu and McKeehan, 2002), 
MAP1A and MAP1B are larger proteins (> 300 kDa) and only expressed in the central and 
peripheral nervous system (Noiges et al., 2002; Togel et al., 1998). All three proteins are 
synthesized as polyprotein precursors that are subsequently cleaved into a heavy and light 
chain. The two chains can subsequently reassociate or exert separate functions (Schoenfeld 
and Obar, 1994). Having identified the light chain 1 of MAP1B as a potential interactor in the 
yeast two-hybrid screen, I went on to confirm MAP1B-LC1 as an interactor in a mammalian 
cell system. Transfection of HEK293T cells with plasmids encoding control vector, myc-
FBXO7 and FLAG-LC1 followed by co-immunoprecipitation analyses with either of the 
possible antibody combinations revealed the specific interaction of FBXO7 and MAP1B-LC1 
(Figure 2.8 a, b, c).  
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Figure 2.8: FBXO7 interacts with MAP1B-LC1: (a) Schematic representing the MAP1 protein familiy. 
Dashed line represents the cleavage site between heavy chain (HC) and light chain (LC). M= Microtubule-
binding domain, A= Actin-binding domain, Yellow box= highly similar MAGD domain. Adapted from {genome 
biol, 2006, halpain} (b) At least 1 mg of lysates from HEK293T cells, transfected with either myc-FBXO7 or 
FLAG-LC1 together with appropriate control vectors or both myc-FBXO7 and FLAG-LC1 plasmids, were 
subjected to IP (immunoprecipitation) with the FLAG antibody and subsequent immunoblotting using the myc 
antibody. 50 μg of total cell lysate was subjected to IB (immunoblotting) using the same antibodies and served 
as an input control. Arrowhead indicates specific interaction band. IgGH indicates the heavy chain of the IP 
antibody. (c) At least 1 mg of lysates from HEK293T cells transfected with either myc-FBXO7 or FLAG-LC1 
together with appropriate control vectors or both myc-FBXO7 and FLAG-LC1 plasmids were subjected to IP 
with the myc antibody and subsequent immunoblotting using the FLAG antibody. 50 μg of total cell lysate was 
subjected to immunoblotting using the same antibodies and served as an input control.  Arrowhead indicates 
specific interaction band. IgGH indicates the heavy chain of the IP antibody. 
 
To investigate which domain of FBXO7 was responsible for LC1-binding, I carried out 
a mapping analysis using FBXO7 deletion mutants (Figure 2.9 a). Co-immunoprecipitation 
analyses using transfected HEK293T cells with the control vector or the myc-FBXO7 deletion 
mutants together with FLAG- MAP1B-LC1 identified the amino acids 1 - 180, which include 
the ubiquitin-like (Ubl) domain, as indispensable for the interaction (Figure 2.9 b). I 
furthermore investigated which of the known domains on MAP1B-LC1 was responsible for the 
interaction with FBXO7 and generated three LC1 deletion mutants (Figure 2.9 c). Using 
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HEK293T cells transfected with the control vector or either of the FLAG-LC1 deletion mutants 
along with myc-FBXO7 identified the 25-amino acid mitochondrial aggregation and genome 
destruction (MAGD) domain (Liu et al., 2005) as the specific region of interaction (Figure 2.9 
d).  
 
Figure 2.9: Mapping analysis of the FBXO7-LC1 interaction: (a) Schematic representation of FBXO7 
deletion ( ) mutants. WT= wild type, NT= N-terminus, FP= FBXO7-PI31 interaction domain, CT= C-terminus, 
F-box= F-box domain, PRR= proline-rich region. (b) At least 1 mg of lysates from HEK293T cells, transfected 
with either FLAG-LC1 or myc-FBXO7 with respective control vectors or FLAG-LC1 together with either the 
myc-FBXO7 WT, NT, FP, CT, F-box or PRR plasmid were subjected to IP with the myc antibody and 
subsequent IB using the FLAG antibody. 50 μg of total cell lysate was subjected to IB using the same 
antibodies and served as input control. Arrowheads indicate specific interaction bands. IgGH indicates the 
heavy chain of the IP antibody. (c) Schematic representation of MAP1B-LC1 mutants. WT= wild type, MTB= 
Microtubule-binding domain only, MTB= Lacking the microtubule-binding domain, MAGD= Lacking the 
mitochondrial aggregation and genome destruction, AB= Actin-binding domain (d) At least 1 mg of lysates 
from HEK293T cells, transfected with either myc-FBXO7 or FLAG-LC1 with respective control vectors or myc-
FBXO7 together with either FLAG-LC1, MTB, MTB or MAGD were subjected to IP with the FLAG antibody 
and subsequent IB using the myc antibody. 50 μg of total cell lysate was subjected to IB using the same 
antibodies and served as an input control. Arrowhead indicates specific interaction band. IgGH indicates the 
heavy chain of the IP antibody. 
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Since this domain displays high sequence similarity between LC1 of MAP1B, LC2 of 
MAP1A and MAP1S, I wondered whether LC2 and MAP1S would also interact with FBXO7. 
Co-immunoprecipitation analyses of HEK293T cells transfected with control or myc-FBXO7 
along with either FLAG-LC2 or full-length FLAG-MAP1S identified two more interactors of 
FBXO7 (Figure 2.10 a, b) and furthermore elucidates the MAGD region as the specific 
FBXO7-binding motif. 
 
Figure 2.10: FBXO7 also interacts with the MAP1 family members MAP1A-LC2 and MAP1S: (a) At least 
1 mg of lysates from HEK293T cells, transfected with either myc-FBXO7 or FLAG-LC2 together with 
appropriate control vectors or myc-FBXO7 and FLAG-LC2 together were subjected to IP with the FLAG 
antibody and subsequent IB using the myc antibody. 50 μg of total cell lysate was subjected to IB using the 
same antibodies and served as an input control. Arrowhead indicates specific interaction band. IgGH indicates 
the heavy chain of the IP antibody. (b) At least 1 mg of lysates from HEK293T cells, transfected with either 
myc-FBXO7 or FLAG-MAP1S with respective control vectors or myc-FBXO7 and FLAG-MAP1S together were 
subjected to IP with the FLAG antibody and subsequent IB using the myc antibody. 50 μg of total cell lysate 
was subjected to IB using the same antibodies and served as an input control. Arrowhead indicates specific 















2.7 The MAP1 family proteins are potential ubiquitination substrates 
of FBXO7-SCF 
Having established MAP1B-LC1, MAP1A-LC2 and MAP1S as novel FBXO7 
interaction partners, I asked whether these proteins could be potential ubiquitination 
substrates of FBXO7. Co-expression analyses of control, myc-FBXO7 WT or myc-FBXO7 F-
box (a mutant lacking the E3 ligase activity-conferring domain) with FLAG-LC1 or FLAG-LC2 
resulted in the appearance of a higher molecular weight smear that was sensitive to ligase 
activity of FBXO7 (Figure 2.11 a, c brackets) suggesting that it might be ubiquitin 
modification. This effect was specific to FBXO7, since co-expression of another F-box protein 
FBXO31 did not result in the same effect (Figure 2.11 b, d). Furthermore, co-expression of 
HA-tagged ubiquitin enhanced the intensity of the higher molecular weight signals on FLAG-
LC2 indicating that the observed modification might be ubiquitination (Figure 2.11 e). As 
compared to wild type ubiquitin, a ubiquitin mutant that was unable to form lysine (K) 63-
linked chains diminished the appearance of the smear whereas another ubiquitin variant 
harboring the K48R mutation did not diminish the smear (Figure 2.11 e). As compared to 
LC2, LC1 appeared as a double band in the co-expression analysis independent of FBXO7. 
To investigate, whether one of the bands was a phosphorylated form of LC1, I treated 
transfected HEK293T lysates with λ-protein phosphatase. Indeed, the upper band of FLAG-
LC1 was responsive to λ-protein phosphatase treatment while FBXO7 did not show any 
response (Figure 2.11 f). SP1 served as a positive control and displayed a shift indicative of 
a loss of phosphorylation. Taken together, I confirmed MAP1B-LC1, MAP1A-LC2 and MAP1S 
as novel interaction partners of FBXO7 and furthermore presented data suggesting that LC1 
and LC2 could be potential ubiquitination substrates of FBXO7. Further experiments, such as 
in vivo or in vitro ubiquitination assays are required to confirm this hypothesis. 
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Figure 2.11: LC1 and LC2 proteins are modified in a FBXO7-dependent manner: (a) Lysates from 
HEK293T cells, transfected with either myc-FBXO7 or FLAG-LC1 together with appropriate control vectors as 
well as FLAG-LC1 together with either myc-FBXO7 WT or F-box plasmid, were subjected to IB using the 
FLAG, myc or 14-3-3 antibodies, respectively. The latter served as a loading control. The bracket indicates 
smear. (b) Lysates from HEK293T cells, transfected with either myc-FBXO31 or FLAG-LC1 together with 
appropriate control vectors as well as FLAG-LC1 together with myc-FBXO31, were subjected to 
immunoblotting using the FLAG, myc or 14-3-3 antibodies, respectively. The latter served as a loading control. 
Arrowheads indicate the LC1 protein bands. (c) Lysates from HEK293T cells, transfected with either myc-
FBXO7 or FLAG-LC2 with respective control vectors as well as FLAG-LC2 together with either myc-FBXO7 
WT or F-box, were subjected to immunoblotting using the FLAG, myc or 14-3-3 antibodies, respectively. The 
latter served as a loading control. The bracket indicates smear. (d) Lysates from HEK293T cells, transfected 
with either myc-FBXO31 or FLAG-LC2 with respective control vectors as well as FLAG-LC2 together with 
myc-FBXO31, were subjected to IB using the FLAG, myc or 14-3-3 antibodies, respectively. The latter served 
as a loading control. (e) Lysates from HEK293T cells, transfected with either myc-FBXO7 or FLAG-LC2 
together with appropriate control vectors as well as FLAG-LC2 together with myc-FBXO7 WT along with one 
of the indicated HA-Ubiquitin variant plasmids were subjected to IB using the FLAG, myc or 14-3-3 antibodies, 
respectively. The latter served as a loading control. The bracket indicates smear. (f) 75 μg of lysates from 
HEK293T cells, transfected with myc-FBXO7 and FLAG-LC1 were incubated with or without addition of λ-
protein phosphatase for 1 h at 37°C and subjected to IB using the FLAG, SP1 or myc antibodies. 
 
2.8 FBXO7 binds to the proteasome via its novel interaction partner 
PSMA2 (proteasomal subunit alpha 2) 
Another novel interaction protein identified in the screen was the proteasomal subunit 
alpha 2 (PSMA2) (Table 2.1). To determine whether PSMA2 is a novel interactor of FBXO7, I 
transfected HEK293T cells with plasmids encoding control vector, myc-FBXO7 and FLAG-
PSMA2 and subjected them to co-immunoprecipitation analyses. Specific interaction bands in 
the experimental as compared to the control conditions confirmed the interaction of FBXO7 
and PSMA2 (Figure 2.12 a, b).  
 
Figure 2.12: FBXO7 interacts with PSMA2: (a) Lysates from HEK293T cells, transfected with either myc-
FBXO7 or FLAG-PSMA2 together with appropriate respective control vectors or both myc-FBXO7 and FLAG-
PSMA2 plasmids were subjected to IP with the FLAG antibody and subsequent IB using the myc antibody. 50 
μg of total cell lysate was subjected to IB using the same antibodies and served as an input control. 
Arrowhead indicates specific interaction band. IgGH indicates the heavy chain of the IP antibody. (b) Lysates 
from HEK293T cells, transfected with either myc-FBXO7 or FLAG-PSMA2 together with appropriate 
respective control vectors or both myc-FBXO7 and FLAG-PSMA2 plasmids were subjected to IP with the myc 
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antibody and subsequent IB using the FLAG antibody. 50 μg of total cell lysate was subjected to IB using the 
same antibodies and served as an input control.  Arrowhead indicates specific interaction band. IgGL 
indicates the light chain of the IP antibody. 
 
To investigate, which domain of FBXO7 was responsible for PSMA2-binding, I made 
use of FBXO7 deletion mutants lacking either of its known protein domains (Figure 2.13 a). 
Co-immunoprecipitation analysis in HEK293T cells transfected with control vector or either of 
the myc-FBXO7 deletion mutants along with FLAG-PSMA2 identified the N-terminal ubiquitin-
like (Ubl) domain as the interacting domain (Figure 2.13 b). Furthermore, I tested whether 
one of the known patient mutations located at the N-terminus of FBXO7 (T22M) might 
interfere with its interaction with PSMA2 and found no difference in the quality of the 
interaction (Figure 2.13 c).  
 
Figure 2.13: FBXO7 interacts with PSMA2 via its Ubl-domain: (a) Schematic representation of FBXO7 
deletion ( ) mutants. WT= wild type, Ubl= ubiquitin-like, FP= FBXO7-PI31 interaction domain, NT= N-
terminus, PRR= proline-rich region, CT= C-terminus. (b) Lysates from HEK293T cells, transfected with either 
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FLAG-PSMA2 or myc-FBXO7 with together with appropriate control vectors or FLAG-PSMA2 together with 
either myc-FBXO7 WT, Ubl, FP, NT, PRR or CT plasmid were subjected to IP with the myc antibody 
and subsequent IB using the FLAG antibody. 50 μg of total cell lysate was subjected to IB using the same 
antibodies and served as an input control. Arrowhead indicates specific interaction band. IgGL indicates the 
heavy chain of the IP antibody. (c) Lysates from HEK293T cells, transfected with GFP-PSMA2 together with 
control, myc-FBXO7 WT or myc-FBXO7-T22M were subjected to IP with the GFP antibody and subsequent IB 
using the myc antibody. 50 μg of total cell lysate was subjected to IB using the same antibodies and served as 
an input control. 
 
FBXO7 has been shown to interact with the proteasome-interacting protein PI31 (Kirk 
et al., 2008) and was moreover identified in two mass spectrometry studies designed to 
identify novel proteasome regulators (Bousquet-Dubouch et al., 2009; Fabre et al., 2015). 
Although biochemical evidence is still missing, these studies suggest that FBXO7 
constitutively binds to the proteasome in a constitutive or transient manner and that FBXO7 
may regulate proteasomal processes. To provide biochemical evidence for FBXO7’s 
interaction with the proteasome, I carried out a glycerol gradient density centrifugation. For 
this, I fractionated transfected HEK293T cell lysates overexpressing either myc-FBXO7 WT, 
myc-FBXO7 Ubl or myc-FBXO7 FP, the latter two representing loss-of-binding mutants for 
PSMA2 or PI31, respectively. In the 10 - 40% glycerol gradient, the proteasomes sedimented 
in the bottom fractions. Since proteasomes exist in different assembly forms, which is 
reflected by the difference in sedimentation coefficients, I observed two peaks of enrichment 
that represent these forms. Immunoblotting for PSMB5, a subunit of the 20S core, revealed 
an enrichment between fractions 10 - 12 and fractions 14 - 16 (Figure 2.14 a). Due to the 
simultaneous presence of the 19S cap protein Rpt6 and the 20S core markers, fractions 14 - 
16 were identified as the 26S / 30S proteasome fractions, whereas fractions 10 - 13 are likely 
to contain 20S particles as well as 20S particles associated with alternative regulatory 
particles. Overexpressed FBXO7 was enriched in the top fractions 3 – 5 and is likely to 
represent cytoplasmic forms of FBXO7. In addition, a substantial amount of FBXO7 co-
fractionated with the different proteasome forms in fractions 8 - 13 and to a lesser degree in 
fractions 14 - 20 (Figure 2.14 a). Deletion of the PSMA2-interaction domain led to a complete 
loss of co-fractionation with the proteasome-enriched fractions and an accumulation of the 
myc-FBXO7 Ubl mutant in fractions 3 - 5 (Figure 2.14 b) suggesting that PSMA2-binding is 
required for FBXO7’s association with the proteasome. In contrast, interaction with PI31 was 
not required for co-fractionation of FBXO7 in the proteasome-enriched fractions as deletion of 
the PI31-interaction domain did not result in a change in the distribution pattern of FBXO7 
(Figure 2.14 c). The distribution of myc-FBXO7 FP, however, seemed to be shifted by one 
fraction towards bottom glycerol concentrations, which can be explained by the reduced size 
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and hence molecular weight of this mutant (Figure 2.14 c, 2.13 a). Taken together, I 
identified the proteasomal core subunit PSMA2 as a novel interaction partner of FBXO7, 
mapped the PSMA2-interacting domain to the N-terminal Ubl-domain and provided 
biochemical evidence that FBXO7 associates with the proteasome holozenzyme by binding 
to PSMA2. 
 
Figure 2.14: FBXO7 associates with the proteasome in a Ubl-domain-dependent manner: (a, b, c) 
Lysates from HEK293T cells, transfected with either myc-FBXO7 WT (a), myc-FBXO7 Ubl (b) or myc-
FBXO7 FP (c) were separated by glycerol gradient centrifugation, fractionated and subjected to IB using the 
FBXO7, Rpt6 or PSMB5 antibodies. The latter two served as fraction controls for 26S + 30S or 20S 
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proteasomes, respectively. (d) Input control for (a, b, c), 50 μg of total cell lysate was subjected to IB using the 
myc and GAPDH antibodies. The latter served as a loading control. 
2.9 FBXO7 ubiquitinates PSMA2 mainly by K63-linked chains with a 
non-proteolytic outcome 
Having identified PSMA2 as an FBXO7 interaction partner the next question was 
whether it also is an ubiquitination target. A first hint that this would be the case came from a 
co-expression analysis in HEK293T cells using control vector, myc-FBXO7 WT or F-box (a 
mutant lacking the E3 ligase activity-conferring F-box domain) with FLAG-PSMA2. Under 
these conditions, only co-expression of PSMA2 with FBXO7 WT but not FBXO7 F-box or 
control vector led to the appearance of a typical ladder-like pattern above the wild type form 
of PSMA2, indicative of ubiquitination (Figure 2.15 a). Co-expression of another F-box 
protein FBXO31 did not trigger to this response (Figure 2.15 b) suggesting a FBXO7- and E3 
ligase-dependent modification of PSMA2.  
 
Figure 2.15: PSMA2 is modified in a FBXO7-dependent manner: (a) Lysates from HEK293T cells, 
transfected with either myc-FBXO7 or FLAG-PSMA2 together with appropriate control vectors as well as 
FLAG-PSMA2 together with either myc-FBXO7 WT or F-box were subjected to IB using the FLAG, myc or 
14-3-3 antibodies, respectively. The latter served as a loading control. The bracket indicates smear. (b) 
Lysates from HEK293T cells, transfected with either myc-FBXO31 or FLAG-PSMA2 with respective control 
vectors as well as FLAG-PSMA2 together with myc-FBXO31 were subjected to immunoblotting using the 










To confirm that this was indeed ubiquitination, I carried out a cell-based ubiquitination 
assay for which I transfected HEK293T cells with control vector, myc-FBXO7 WT or myc-
FBXO7 F-box along with GFP-PSMA2 and subjected them to a lysis protocol under 
denaturing conditions to avoid contamination of PSMA2 by unspecifically binding proteins. 
The following immunoprecipitation for GFP-PSMA2 and subsequent immunoblotting with a 
ubiquitin antibody specific for higher molecular weight ubiquitin chains revealed a ubiquitin-
positive smear (Figure 2.16 a). The same experimental conditions were used with a different 
antibody, which recognizes all forms of ubiquitin conjugates (Figure 2.16 b) confirming that 
FBXO7 indeed modifies PSMA2 by ubiquitination. Due to the denaturing lysis conditions, all 
FBXO7 should have ideally been removed from the PSMA2-precipitates. To control for any 
possible contribution of FBXO7 autoubiquitination to the ubiquitin signal, I carried out a cell-
based ubiquitination assay as described before, transfecting only control vector, myc-FBXO7 
WT or myc-FBXO7 F-box and immunoprecipitating for myc-FBXO7 followed by 
immunoblotting with different ubiquitin antibodies. None of the ubiquitin antibodies detected a 
ubiquitin smear (Figure 2.16 c) suggesting that FBXO7 does not have a high constitutive 
autoubiquitination activity and furthermore confirming the specificity of ubiquitination to 
PSMA2 in the previous experiments.  
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Figure 2.16: FBXO7 ubiquitinates PSMA2: (a) Lysates from HEK293T cells, transfected with GFP-PSMA2 
together with either control, FBXO7 WT or FBXO7 F-box were subjected to a denaturing lysis protocol, 
followed by IP using the GFP antibody. Subsequently, precipitated proteins were immunoblotted using the 
ubiquitin antibody (DAKO). Ubn indicates the ubiquitin-reactive smear. IgGH indicates the heavy chain of the 
IP antibody. 50 μg of total cell lysate was subjected to IB using the GFP and myc antibodies, serving as an 
input control. (b) Lysates from HEK293T cells, were transfected and treated as described in (a) followed by IB 
using the ubiquitin antibody (sc-P4D1). (c) Lysates from HEK293T cells, transfected with either control vector, 
FBXO7 WT or FBXO7 F-box, subjected to a denaturing lysis protocol and subsequently immunoblotted with 
the DAKO, K63 polyubiquitin-specfic or K48 polyubiquitin-specific antibodies. IgGH indicates the heavy chain 
of the IP antibody. 50 μg of total cell lysate was subjected to IB using the myc antibody, serving as an input 
control. 
 
A general concept of gene mutations is interference with the protein function. To test 
whether any of the reported gene mutations of FBXO7 is interfering with its E3 ligase activity, 
I subjected HEK293T cells transfected with control vector, myc-FBXO7 WT, the mutants 
T22M, R378G, R498X and the SNP M115I along with GFP-PSMA2 and tagged HA-Ubiquitin 
to a denaturing lysis protocol. No ablation of the previously seen ubiquitination smear could 
be observed (Figure 2.17), suggesting that none of the investigated mutants are interfering 
with FBXO7's E3 ligase function.  
 
Figure 2.17: FBXO7 mutations do not affect its ligase activity: Lysates from HEK293T cells, transfected 
with HA-Ubiquitin and GFP-PSMA2 together with either control, FBXO7 WT, T22M, M115I, R378G or R498X 
were subjected to a denaturing lysis protocol, followed by IP using the GFP antibody. Subsequently, 
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precipitated proteins were immunoblotted using the HA antibody. Ubn indicates the ubiquitin-reactive smear. 
IgGH indicates the heavy chain of the IP antibody. 50 μg of total cell lysate was subjected to IB using the GFP 
and myc antibodies, serving as an input control. 
 
Attachment of ubiquitin to a substrate protein can occur in different modes, either as 
mono-, multimono-conjugates or polyubiquitin. The latter chains require the specific usage of 
lysine residues on ubiquitin to assemble polyubiquitin chains. Different types of ubiquitination 
have a different functional outcome for the protein. The prominent ladder patterns observed in 
total cell lysates of co-expression of FBXO7 and PSMA2 show distinct bands at molecular 
weights which correspond to the size of attachment of mono- or multimono- ubiquitin moieties 
(Figure 2.15 a, 2.16 a - Input panel).  
The consistent stability of the ubiquitinated forms of PSMA2 also suggests that the 
functional outcome of the ubiquitination is non-proteolytic. To examine the type of ubiquitin 
chain by which PSMA2 is modified (Figure 2.9 b), I subjected HEK293T cells to the same 
protocol as described, followed by immunoblotting with antibodies specific for either K48- or 
K63-linked ubiquitin chains. While the K63-specific antibody revealed an increase in smear, 
the K48-specific antibody did not (Figure 2.18 a). I furthermore took advantage of HA-
Ubiquitin variants that carry mutations in either the lysine residue 48 or 63 and are hence 
unable to form ubiquitin chains of the respective type. Immunoblotting for the HA antibody 
revealed that as compared to wild type, mutation of the lysine residue 48 did not lead to a 
decreased intensity of the smear, while mutation of the lysine 63 residue did (Figure 2.18 b). 
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Figure 2.18: FBXO7 ubiquitinates PSMA2 mainly by K63-linked polyubiquitination: (a) Lysates from 
HEK293T cells, transfected with GFP-PSMA2 together with either control, FBXO7 WT or FBXO7 F-box were 
subjected to a denaturing lysis protocol, followed by IP using the GFP antibody. Subsequently, precipitated 
proteins were immunoblotted using the K63 polyubiquitin-specfic or K48 polyubiquitin-specific antibodies. 
IgGH indicates the heavy chain of the IP antibody. 50 μg of total cell lysate was subjected to IB using the GFP 
and myc antibodies, serving as an input control. (b) Lysates from HEK293T cells transfected with 
combinations of plasmids encoding GFP-PSMA2, control, myc FBXO7 WT or F-box and HA-Ubiquitin WT or 
the indicated linkage-mutant, respectively, were subjected to a denaturing lysis protocol, followed by IP using 
the GFP antibody. and immunoblotting with the HA antibody. Ubn indicates the ubiquitin-reactive smear. IgGH 
indicates the heavy chain of the IP antibody. 50 μg of total cell lysate was subjected to IB using the GFP, myc 
and HA antibodies, serving as an input control. 
 
 Collectively, these results suggest that FBXO7 ubiquitinates PSMA2 and that the 
modification might be mono- or multimono-ubiquitin in addition to lysine 63-linked 
polyubiquitin chains.  
To confirm that the outcome of ubiquitination was indeed non-proteolytic, I compared 
PSMA2 protein levels in cortical lysates of P18 FBXO7+/+ and FBXO7-/- mice and found no 
change (Figure 2.19 a, b). Furthermore, PSMA2 protein levels were not notably changed in 
response to knockdown of FBXO7 in HEK293T cells (Figure 2.22 c), strengthening the idea 
that the consequence of PSMA2 ubiquitination by FBXO7 is a functional modification rather 
than degradation. 
 
Figure 2.19: PSMA2 stability is not affected in FBXO7-/- animals: (a) P18 cortical lysates of FBXO7+/+ 
and FBXO7-/- mice were subjected to immunoblotting with the PSMA2 and γ-tubulin antibodies. The latter 
served as a loading control. (b) Densitrometric quantification of PSMA2 protein levels in (a). n= 10 FBXO7 
litterpairs were analyzed (Paired t-test, ns= non significant, mean + s.e.m.). 
 
Results 
2.10 FBXO7 is required for proper proteasomal assembly and function 
41 
 
2.10 FBXO7 is required for proper proteasomal assembly and 
function  
As a subunit of the proteasome core complex, PSMA2 regulates the gating of 
unfolded protein chains into the proteolytic chamber as well as the assembly of the 20S core 
complex with the 19S regulatory complex (Kish-Trier and Hill, 2013). Functional modification 
of PSMA2 by FBXO7 would hence be expected to have an impact on either function.  
 
2.10.1 Proteasome activity is reduced as a result of FBXO7-deficiency 
To first investigate whether proteasome activity in general was affected, I subjected 
whole brain lysates of P18 FBXO7+/+ and FBXO7-/- mice to a proteasome activity assay 
protocol. Lysates from aforementioned littermates were incubated with the artificial 
fluorogenic peptide substrate Suc-LLVY-AMC, which is specifically recognized and cleaved 
by the main protease activity of the proteasome resulting in the release of the fluorophore and 
the emission of light. As compared to the wild type littermate, brain lysates of FBXO7-/- mice 
displayed reduced proteasome activity (Figure 2.20 a, b). This result was further 
corroborated by knockdown of endogenous FBXO7 in the HEK293T heterologous cell 
system, resulting in a corresponding decrease in proteasome activity (Data Siv Vingill).  
 
Figure 2.20: Proteasome activity is decreased in the FBXO7-/- brain: (a) P18 whole brains of FBXO7+/+ 
and FBXO7-/- mice were subjected to a detergent-free lysis protocol. Lysates were incubated with the 
chymotrypsin-like proteasome activity substrate Suc-LLVY-AMC. Proteasome activity was measured at 0, 30, 
60 and 90 min, respectively. Lysates from three independent FBXO7 litters were analyzed and the relative 
fluorescence normalized to the FBXO7+/+ endpoint quantified (ANOVA, *p<0.05, **p<0.01, mean + s.e.m.). 
(b) P18 whole brain lysates from (a) were subjected to immunoblotting using the β-Gal and 14-3-3 antibodies. 
The latter served as a loading control. 
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2.10.2 Loss of FBXO7 does not affect proteasomal gating 
To find out whether the decrease in proteasome activity was a result of less efficient 
gating of single proteasomes, I subjected cortical lysates of four pooled P18 FBXO7+/+ and 
FBXO7-/- mice, respectively, to an affinity purification protocol for 26S proteasomes. In this 
protocol, cortical lysates were incubated with the GST-tagged Ubl-domain of RAD23B, which 
binds 26S proteasomes with high affinity allowing the precipitation of 26S proteasome-
RAD23B-Ubl complexes from the lysates. Elution of the 26S proteasome complexes from 
GST-beads was achieved by binding competition for the RAD23B Ubl-domain with the His10-
tagged UIM-domain of S5a followed by removal of excess His10-UIM with Ni
2+-NTA beads. 
The obtained purified 26S proteasome fractions displayed the typical protein band pattern of 
26S proteasomes on Coomassie Blue-stained SDS-PAGE gels and had little or no impurities 
(Figure 2.21 a). Subsequently, 25 μg of purified proteasomes from FBXO7+/+ and FBXO7-/- 
brains were resolved by native PAGE and the gel incubated with the artificial substrate Suc-
LLVY-AMC. Both FBXO7+/+ and FBXO7-/- proteasomes displayed comparable activities 
(Figure 2.21 b, c) suggesting that FBXO7-mediated modification of PSMA2 is not required 
for proper proteasomal substrate gating or proteasome activity per se. 
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Figure 2.21: Assembled proteasomes from FBXO7-/- mice are functionally active: (a) Pooled cortical 
lysates of four P18 FBXO7+/+ and FBXO7-/- mice, respectively, were subjected to an affinity purification 
protocol of 26S proteasomes. GST-tagged RAD23B-Ubl was added to the lysates, binding the 26S 
proteasomes and subsequently isolated via GST-beads. Proteasomes were eluted from the beads by 
competition with the His10-tagged UIM of S5a. Excess His10-UIM was removed by binding to Ni
2+
-NTA beads. 
Fractions of each purification step were resolved by SDS-PAGE and stained with the Coomassie blue dye. 
Asterisk indicates GST-UBL, arrowheads indicate His10-UIM. (b) 25 μg of purified proteasomes were resolved 
by native PAGE and the gel subsequently incubated with Suc-LLVY-AMC for 10 min at 37°C. The gel was 
exposed to UV light and photographed. (c) The same native PAGE gel from (a) was subjected to western 
blotting and immunoblotted with the PSMA2 antibody. 
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2.10.3 Loss of FBXO7 causes incomplete assembly of the proteasome holoenzyme 
With proteasome gating remaining functional upon loss-of-FBXO7, the next question 
was whether proteasome assembly was affected. To test this, I took advantage of a native 
PAGE gel analysis protocol allowing the visualization of proteasome complexes from cell 
lysates. HEK293T cell lysates were transfected with empty control vector or RNAi plasmids 
encoding functional or non-functional FBXO7 shRNA and resolved by native PAGE, followed 
by incubation of the gel with the artificial substrate Suc-LLVY-AMC. Knockdown of FBXO7 
resulted in a marked increase of free 20S core particles (CP), which was already visible prior 
to the stimulation of the latent 20S CP activity with low concentrations of SDS (Figure 2.22 
a). While the abundance of single-capped (RP1-CP), so-called 26S proteasomes was 
comparable between knockdown and the controls, the levels of double-capped (RP2-CP), 
30S proteasomes was reduced. To confirm, that the differences in the different assembly 
states of proteasomes reflected changes in abundance of the respective proteasome species 
and not differences in their activity, the same native PAGE gel was subjected to 
immunoblotting using the PSMA2 antibody. The results confirmed the overabundance in the 
FBXO7 RNAi condition (Figure 2.22 b). Analysis of the total cell lysates additionally showed 
however that total PSMA2 levels were not increased, suggesting that the increase in free 20S 
core particles was indeed due to assembly deficits of 26S or 30S proteasomes and not 
increased production of 20S proteasomes (Figure 2.22 c). Furthermore, I immunoblotted the 
same experimental conditions analyzed on native PAGE with the antibody against the 
proteasome cap subunit Rpt6. This experiment confirmed the decrease in 30S proteasome 
particles and furthermore revealed an increase in free 19S caps (Figure 2.22 d), which was 
due to assembly deficits and not due to an increase in 19S cap production since Rpt6 levels 
were comparable in total cell lysates (Figure 2.22 e).  
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Figure 2.22: FBXO7 is required for proteasome assembly: (a) Lysates from HEK293T cells, transfected 
with either control, functional FBXO7 shRNA or non-functional control shRNA were subjected to a detergent-
free lysis. Lysates were resolved by native PAGE and the gel subsequently incubated with Suc-LLVY-AMC for 
10 min at 37°C in the absence of SDS, followed by 10 min at 37°C in the presence of 0.02 % SDS. After each 
incubation, the gel was exposed to UV light and photographed. (b) The same native PAGE gel from (a) was 
subjected to IB with the PSMA2 antibody. (c) Input control for (a) and (b), 50 μg of total cell lysate was 
subjected to IB using the FBXO7, PSMA2 and γ-tubulin antibodies. The latter served as a loading control. (d) 
Lysates from HEK293T cells, transfected with either control, functional FBXO7 shRNA or non-functional 
control shRNA and subjected to a detergent-free lysis protocol. Lysates were resolved by native PAGE and 
immunoblotted with the Rpt6 antibody. (e) Input control for (d), 50 μg of total cell lysate was subjected to IB 
using the Rpt6 and 14-3-3 antibodies. The latter served as a loading control. (f) Cortices of P18 FBXO7+/+ 
and FBXO7-/- mice were subjected to a detergent-free lysis protocol. Lysates were resolved by native PAGE 
and the gel subsequently incubated with Suc-LLVY-AMC for 10 min at 37°C in the absence of SDS, followed 
by 10 min at 37°C in the presence of 0.02 % SDS. After each incubation, the gel was exposed to UV light and 
photographed. (g) The native PAGE gel from (f) was subjected to IB with the PSMA2 antibody. (h) 50 μg of 
total cell lysate was subjected to IB using the β-Gal, FBXO7 and γ-tubulin antibodies. The latter served as a 
loading control. 
 
Having observed an assembly deficit under short-term conditions of reduced FBXO7 
protein levels, I wondered whether this was also true in the FBXO7-/- representing a long-
term and complete loss-of-FBXO7. To address this question, I resolved cortical lysates of 
P18 FBXO7+/+ and FBXO7-/- mice by native PAGE and subjected the gel to incubation with 
the artificial substrate Suc-LLVY-AMC followed by immunoblotting with the PSMA2 antibody. 
Both analyzed litterpairs displayed increased levels of free 20S proteasomes in activity and 
western blot as well as a decrease of 30S proteasomes in western blot (Figure 2.22 f, g, h) 
confirming the results observed under knockdown of FBXO7.  
Investigation of the proteasome profile by native PAGE provides a rapid, qualitative 
tool for profiling of the different assembly states of the proteasome but it lacks a fine, 
quantitative consideration of the distribution of the proteasome forms as well as their activity 
levels. To achieve this, I performed glyerol gradient density centrifugation analyses of 
HEK293T lysates transfected with empty control vector, functional shRNA or non-functional 
FBXO7 shRNA. As compared to exogenously overexpressed FBXO7 (Figure 2.14 a), 
endogenous FBXO7 protein was also enriched in fractions 3 - 5 and displayed co-
fractionation with the proteasome-enriched fractions 8 - 17, however to lower amounts 
(Figure 2.23 a). Knockdown of FBXO7 expectedly led to a total decrease in FBXO7 protein 
as well as a decrease in the proteasome fractions (Figure 2.23 b). Measurement of 
proteasome activity of the control-transfected lysates revealed one major peak of activity in 
the 26S and 30S proteasome-enriched fractions 14 - 16 (Figure 2.23 c). FBXO7 shRNA-
transfected cells in contrast displayed a narrower major peak and additionally a smaller peak 
in the fractions 12 - 14. Measurement of proteasome activity upon SDS treatment, lead to a 
stimulation of the latent 20S proteasome activity and resulted in the expected appearance of 
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an activity peak in the fractions 11 and 12 for the control (Figure 2.23 d). In accordance with 
the data acquired by native PAGE proteasome profiling, knockdown of FBXO7 led to an 
increase of the stimulated 20S peak in fractions 11 and 12 as well as a narrower second peak 
(Figure 2.23 d).  
Collectively, these results suggest that FBXO7 regulates 19S-20S proteasome 
assembly, possibly by its direct association with the proteasome at the 20S core subunit 
PSMA2 and its regulation of protein function by ubiquitination.  
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Figure 2.23: Glycerol gradient analysis of FBXO7 knockdown: (a, b) Lysates from HEK293T cells, 
transfected with either control (a) or FBXO7 shRNA (b) were separated by glycerol gradient centrifugation, 
fractionated and subjected to IB using the FBXO7, Rpt6 or PSMB5 antibodies. The latter two served as 
fraction controls for 26S + 30S or 20S proteasomes, respectively. (c, d) Proteasome activity of fractions 1 - 20 
was determined by incubation with the chymotrypsin-like proteasome activity substrate Suc-LLVY-AMC either 




Parkinson's disease is a highly prevalent neurodegenerative disease of unknown 
cause. In an effort to uncover its etiology, different approaches have been taken. While some 
lines of research focus on the drug-induced disease models, e.g. the MPTP model, others 
take genetic and molecular approaches. Familial cases of PD have provided significant 
starting points by identifying affected genes. Besides the immense fuelling of the alpha-
synuclein field, this has led to the identification of basic mitochondrial quality control 
mechanisms, such as the PINK1/parkin pathway. Also the ubiquitin proteasome system 
(UPS) has been extensively linked to PD but functional insight of UPS components in the 
disease context is still limited. Mutations in the gene encoding the E3 ligase FBXO7-SCF 
have recently been identified in familial cases of PD and shown to lead to the disease 
spectrum PARK15. In this study, I present the effect of loss of the UPS component FBXO7 in 
mice and shed light onto the so far uncharacterized neuropathology thereof. Furthermore, I 
provide further insight into the protein function of FBXO7-SCF by identifying a novel 
ubiquitination substrate. Remarkably, one of the substrates is the alpha 2 subunit of the 
proteasome core and led me to the finding of proteasomal dysfunction in the FBXO7 
knockout brain. My results hence establish the previously anticipated role of FBXO7 in 
proteasomal regulation and furthermore show that UPS deficiency can be involved in the 
etiology of PD. 
 
3.1 Systemic loss of FBXO7 results in detrimental effects on the 
mouse organism 
A previous study showed that FBXO7 mutations lead to a loss of stability of the main 
protein isoform 1 in skin fibroblasts isolated from patients (Zhao et al., 2011). This suggests 
that a loss of protein stability is, at least to a large extent, contributing to the PARK15 loss of 
function mechanism. To model this, we chose a systemic FBXO7 knockout approach using 
mice. Loss of FBXO7 had severe effects on general motor behavior and viability. This was in 
contrast to the mild or absent phenotype in several mouse models of other PARK gene 
knockout mice (Abeliovich et al., 2000; Gautier et al., 2008; Goldberg et al., 2003) and 
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suggests that FBXO7 is a critical component for the entire organism. FBXO7 -/- mice died 
between P19 and P21 without exception (Data Siv Vingill) and could barely move in the end 
stage. This is reminiscent of the bedridden state (Di Fonzo et al., 2009; Yalcin-Cakmakli et 
al., 2014) and premature death (Gunduz et al., 2014; Paisan-Ruiz et al., 2010) of some 
PARK15 patients. To distinguish the potentially negative impact of organic failure on motor 
dysfunction, we also generated conditional knockout mouse lines to investigate the 
contribution of neuronal FBXO7. Deletion of FBXO7 from principal neurons in the forebrain 
resulted in early-onset motor deficits, whereas deletion of FBXO7 in dopaminergic neurons 
displayed hypolocomotion, bradykinesia and alterations of the gait, which are also changed in 
the MPTP model (Data Siv Vingill), (Amende et al., 2005). Taken together, these mouse lines 
recapitulate the main characteristics of the PARK15 spectrum. The variability of pyramidal 
tract signs versus parkinsonian symptoms observed in patients is likely due to the varying 
severity by which the different brain regions are affected in a given genetic background. 
Despite the increasing amount of clinical data on PARK15 patients, the underlying 
neuropathology remains unknown. Since systemic loss of FBXO7 recapitulated the severe 
phenotype of PARK15 patients, I subjected brain sections of these mice to histopathological 
examinations. FBXO7-/- mice displayed significantly increased cell death in the cerebral 
cortex, an effect that I could attribute to the specific loss of FBXO7 by acute knockdown in a 
primary cortical neuron system. This finding was particularly interesting considering that 
cortical atrophy was reported in some of the PARK15 patients (Gunduz et al., 2014; Paisan-
Ruiz et al., 2010). Cerebellar and hippocampal regions displayed a tendency to increased cell 
death, which, however, due to a high variability was not consistent. Furthermore, levels of cell 
death in the midbrain, number of TH-positive neurons in the midbrain (Data Siv Vingill) and 
striatal dopamine were unchanged. This suggested that the nigrostriatal system of FBXO7-/- 
mice at P18 was intact. Based on the patients' response to levodopa treatment, an effect on 
the nigrostriatal system would be expected, however due to the early death of FBXO7-/- 
mice, examination of later degenerative effects was not possible. An absence of nigral neuron 
degeneration is also observed in other PARK gene knockout mouse models (Goldberg et al., 
2005) suggesting that mouse dopaminergic midbrain neurons are more resilient than the 
human ones. Aside from the cell death in the cerebral cortex, I observed increased levels of 
astrogliosis. Astrogliosis can accompany neuronal cell death and is also seen in other 
models, such as the neurotoxic MPTP (Kato et al., 2003) and the genetic ATP13A2 mouse 
model (Kett et al., 2015). Additionally, I did not observe axonal damage or alpha-synuclein-
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positive inclusions. Considering that Lewy bodies are only observed in a few mouse models 
and moreover not a consistent part of the pathology of early-onset parkinsonism patients 
(Poulopoulos et al., 2012) this was not surprising. Taken together, these data demonstrate 
that disruption of the PARK15 gene leads to detrimental consequences for the mouse 
organism. 
 
3.2 FBXO7 and the MAP1 protein family - additional regulators of 
mitochondrial quality control? 
Studies on the protein function of FBXO7 have so far mostly reported ligase-
independent and non-neuronal functions. Thus, identification of novel FBXO7-SCF 
ubiquitination substrates involved in pathways relevant to the neuronal cell system is crucial. 
Since ubiquitination substrates have to physically interact with the ligase, I started my 
analysis by conducting a screen for interaction partners. This screen revealed two novel 
interactors:  
The first interactor was the light chain of microtubule-associated protein 1 B (MAP1B-
LC1). By carrying out mapping analyses, I found the mitochondria accumulation and genome 
destruction (MAGD) domain of LC1 to be responsible for FBXO7-binding. This was 
interesting, since this domain displays a high sequence similarity with MAP1A-LC2 and 
MAP1S/C19ORF5 (Liu et al., 2005). Subsequent identification of MAP1A-LC2 and MAP1S as 
additional and novel interactors confirmed that the highly related MAGD domain is indeed 
responsible for the interaction. While all three MAP1 proteins carry the MAGD domain, its 
function has only been studied in MAP1S. MAP1S is a cytoplasmic protein that is recruited to 
stabilized microtubules. Upon accumulation, it causes aggregation of mitochondria leading to 
cell death and destruction of genomic DNA, for which it uses the eponymous MAGD domain 
(Liu et al., 2005). In contrast to MAP1S, which is expressed in a variety of tissues (Liu and 
McKeehan, 2002) MAP1B and MAP1A are only expressed in developing and adult neuronal 
tissue, respectively (Noiges et al., 2002; Togel et al., 1998). This suggests a critical function 
of MAP1B-LC1 and MAP1A-LC2 in mitochondrial regulation. MAP1B-LC1 has already been 
linked to a mitochondrial function via its S-nitrosylation-dependent degradation by the E3 
ligase MITOL (Yonashiro et al., 2012). However, the mechanism of action exerted by the 
MAGD domain remains unknown. The identification of the highly specific binding of FBXO7 to 
the 25 amino acid MAGD domain suggests that the mitochondrial function of all three MAP1 
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family members is carried out in association with FBXO7.My preliminary experiments also 
suggest, that the FBXO7-MAP1 pathway might involve the ubiquitination of these proteins. 
The recent study by Burchell and colleagues reported a function for FBXO7 in parkin/PINK1-
dependent mitochondrial regulation (Burchell et al., 2013). FBXO7 was shown to bind to 
PINK1 and parkin and facilitate parkin-recruitment to defective mitochondria. This raises the 
question whether FBXO7 binds to mitochondria in a PINK1-dependent manner and which are 
the triggers for FBXO7 translocation. My data indicates the contribution of a MAP1-FBXO7-
dependent pathway to the reported mitochondrial quality control function of FBXO7. 
 
3.3 FBXO7 - a novel proteasome regulating protein  
The other identified interactor was the proteasomal subunit alpha 2 (PSMA2). This 
was particularly interesting because Parkinson's disease and the ubiquitin proteasome 
system have been linked for a long time but mechanistic insight into UPS dysfunction in this 
context is still sparse. Moreover, FBXO7 has been shown to interact with PI31 (proteasomal 
inhibitor 31), a potential proteasome inhibitor (Bader et al., 2011; McCutchen-Maloney et al., 
2000), but FBXO7's contribution to proteasome regulation remained unknown.  
In this study, I show that FBXO7 binds to PSMA2 via its N-terminal ubiquitin-like (Ubl) 
domain. This interaction also mediates the association of FBXO7 with the proteasome, as 
deletion of the Ubl-domain abolished its association with proteasomes. This is consistent with 
previous studies, which show that Ubl domains are typically present in proteins that associate 
with the proteasome. The interaction of Ubl domain-containing proteins with the proteasome 
mostly occurs at the 19S regulatory particle (RP) (Luders et al., 2000; Sakata et al., 2003). 
FBXO7 however uses the Ubl domain to associate with the 20S core particle (CP). Together 
with two recent mass spectrometry studies (Bousquet-Dubouch et al., 2009; Fabre et al., 
2015), my data establishes FBXO7 as a novel proteasome-interacting protein and indicates a 
proteasome-regulating function. To this end, FBXO7 might act on the proteasome on its own, 
or as an E3 ubiquitin ligase complex. Proteasomal subunits are known to be 
posttranslationally modified, including ubiquitination (Cui et al., 2014). Indeed, my data 
revealed that PSMA2 is a ubiquitination substrate of FBXO7 and that the ubiquitination is 
dependent on FBXO7's association with the SCF complex. Correspondingly, also SKP1, 
Cullin1 and Rbx1 have also been detected at proteasomes (Bousquet-Dubouch et al., 2009; 
Verma et al., 2000). Moreover, I showed that FBXO7-dependent ubiquitination of PSMA2 
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occurs mainly via K63-linked ubiquitination and that PSMA2 protein levels are unchanged 
under loss of FBXO7 conditions. This supports the notion that FBXO7 mediates non-
proteolytic ubiquitination and likely induces the functional modification of the target protein. 
Proteasomal alpha subunits have two established functions. The first function is to restrict 
access to the proteolytic chamber by extension of their C-terminal tails to prevent non-specific 
proteolysis of proteins. This process is called gating and gate opening is achieved by binding 
to the RP (Beck et al., 2012; Lander et al., 2012). According to my data however, gating was 
unaffected as purified proteasomes display unaltered activity in loss of FBXO7 conditions. 
The second function of the alpha subunits is to interact with subunits of the RP to promote the 
assembly of proteasome holoenzymes. This process appeared to be affected by loss of 
FBXO7 as seen in an increase of free CP and RPs, and a decrease in proteasome 
holoenzymes associated with two RPs. This observation was intriguing given that in contrast 
to most other alpha subunits, PSMA2 makes additional crucial contact with the RP. All alpha 
subunits are binding to Rpt1-6 proteins of the base of the RP (Lander et al., 2012; Tian et al., 
2011). Due to the asymmetry between the heptameric alpha ring of the core and the 
hexameric AAA-ATPase base of the RP, however, the contacts appear to be rather weak. An 
additional, rather surprising direct interaction has been established between the lid of the RP 
and the CP. Here, the lid subunit Rpn6 directly binds the core subunit PSMA2, stabilizing the 
weak CP and RP interaction (Pathare et al., 2012). Moreover, this link appeared particularly 
stable in reconstructions of core particles with two RPs, but not of those with only one RP (da 
Fonseca and Morris, 2008). This corresponds with my findings that proteasome holoenzymes 
with two RPs appeared to be more affected compared to holoenzymes with only one. 
Collectively, my data indicates that the FBXO7-PSMA2 interaction and the functional 
modification of PSMA2 is essential for maintaining proper proteasome function since free 
CPs are not capable of ubiquitin-dependent degradation under physiological conditions 
(Finley, 2009). 
 
3.4 Conclusion and perspective 
The results from this study establish a role for FBXO7 in regulation of proteasome 
integrity and activity. The importance of the regulation of proteasome assembly by 
posttranslational modification has been reported for the subunit PSMA7, which is 
phosphorylated by protein kinase CK2. PSMA7 phosphorylation appeared to stabilize the 
association of CP and RPs to form proteasome holoenzymes while loss of phosphorylation in 
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response to γ-interferon treatment resulted in unstable holoenzyme complexes (Bose et al., 
2004). With PSMA2, this study also uncovers a novel ubiquitination substrate of the FBXO7-
SCF E3 ligase, which is relevant in the neuronal context. Additionally, a ligase-independent 
interaction of FBXO7 to PSMA2 could also contribute to the observed effects and it would 
hence be interesting to differentiate the binding- from ubiquitination-dependent mechanisms.  
This study strengthens the link between the UPS and PD by uncovering a mechanism 
of proteasome regulation that is dysfunctional in the disease context of PARK15. Moreover, 
FBXO7 seems to be involved in the regulation of two integral cell systems, mitochondria and 
proteasomes. The reciprocity of these systems makes it difficult to trace which of them would 
be affected first by FBXO7 deficiency. Loss of FBXO7-mediated mitochondrial dysfunction 
(Burchell et al., 2013) is known to e.g. lead to an increase in reactive oxygen species (ROS), 
which has been recently reported to result in proteasomal disassembly (Livnat-Levanon et al., 
2014). Conversely, a reduction in proteasome activity has been demonstrated to result in an 
impairment of mitochondrial homeostasis and turnover. Due to FBXO7's potential to localize 
to both the proteasome as well as the mitochondria, FBXO7 could represent a protective 
mechanism of the cell to react to deficiencies in either system. Increased mitochondrial 
dysfunction, e.g. would be anticipated to result in increased translocation of FBXO7 to 
mitochondria, which, in turn would lead to reduced FBXO7 on proteasomes. The 
consequence would be an increase in free core particles, which are thought to be capable of 
the non-specific degradation of oxidized proteins and hence serve as a preventive 
mechanism to restrict ROS-mediated damage (Livnat-Levanon et al., 2014). Under conditions 
with normal mitochondrial function, FBXO7 would be abundantly available to maintain 
physiological levels of associated proteasome holoenzymes. In the case of PARK15, leading 
to a loss of FBXO7, both cell systems are hence affected in their basic functions and would 
be expected to negatively impact on each other leading to high cellular stress levels. The 
degree of cell stress in the different cell-types could be modulated by protective 
compensatory mechanisms inherent to them. Collectively, my findings demonstrate that 
proteasome function and integrity are dependent on FBXO7 function and emphasize UPS 
dysfunction as a major contributing mechanism to PD etiology. 
 
4 Material and Methods 
4.1 Materials 
4.1.1 Chemicals, Reagents and Kits 
Chemicals and reagents used in this study were purchased from Applichem 
(Darmstadt, Germany), Enzo Life Sciences, Inc. (New York, US), GE Healthcare (New 
Jersey, US), Invitrogen (Darmstadt, Germany), Merck (Darmstadt, Germany), Roth 
(Karlsruhe, Germany), Sigma-Aldrich (Munich, Germany), Thermo Fisher Scientific 
(Massachusetts, US), Th. Geyer (Renningen, Germany), Qiagen (Limburg, Netherlands) or 
Worthington (New Jersey, US). Cell culture media and supplements were purchased from 
GibcoTM / Thermo Fisher Scientific. Commercially available kits include the Nucleobond® and 
NucleoSpin® kits for DNA isolation and extraction, respectively, from Macherey-Nagel 
(Dueren, Germany) and the DeadEnd™ Fluorometric TUNEL System (Promega, US). DNA 
and protein ladder markers were obtained from Fermentas / Thermo Fisher Scientific.  
4.1.2 Laboratory Equipment 
The following equipment was used in this study: micropipettes (Gilson, USA), 
consumables and plastic ware (Falcon (Becton Dickinson Labware Europe, Le Pont De Claix, 
France); Eppendorf (Hamburg, Germany); Greiner Bio-One (Frickenhausen, Germany)), 
tabletop and ultracentrifuges (Eppendorf (Hamburg, Germany) and Beckmann Coulter 
(Krefeld, Germany), respectively), rocker and shaker (Heidolph, Germany), thermocycler 
(Biometra, Germany), heater block (Grant Instruments, UK), UV transluminator (Intas, 
Germany), spectrophotometer (Amersham Biosciences, UK), Fluorescent plate reader 
(Wallac 1420 VICTOR2 TM), fluorescent microscope, inverted light microscope and dissection 
microscope (Eclipse Ti, Eclipse TS100 and SMZ645, respectively, from Nikon, Japan), 
brightfield light microscope (Zeiss Axiophot). 
4.1.3 Antibodies 
Primary and secondary antibodies used in this study are listed in Table 4.1 and 4.2. 
 




Table 4.1: List of primary antibodies. 
Primary antibody Application Dilution Host Company 
pan 14-3-3 WB 1:5000 ms Santa Cruz 
α-Synuclein IHC, WB 1:250, 1:1000 rb Cell signaling 
ß-galactosidase WB 1:500 ms Santa Cruz 
γ-Tubulin WB 1:10000 ms Sigma-Aldrich 
APP IHC, WB 1:250, 1:250 ms Thermo Fisher Scientific 
Cleaved caspase-3 ICC 1:200 rb Cell signaling 
Cullin1 WB 1:500 ms Santa Cruz 
Myc WB 1:500 ms Santa Cruz 
Flag WB 1:1000 ms Sigma-Aldrich 
GFP WB 1:500 ms Santa Cruz 
GFP ICC 1:1000 rb Thermo Fisher Scientific 
HA WB 1:500 ms Santa Cruz 
SP1 WB 1:500 ms Santa Cruz 
GFAP IHC 1:200 ms Nova Castra 
Iba1 IHC 1:1000 ms Wako 
Ubiquitin WB 1:500 rb Dako 
Ubiquitin (P4D1) WB 1:500 ms Santa Cruz 
FBXO7 WB 1:500-1:40 ms Santa Cruz 
Ubiquitin K63 WB 1:200 ms Millipore 
Ubiquitin K48 WB 1:200 ms Millipore 
PSMA2 WB 1:1000 rb Cell signaling 
PSMB5 WB 1:1000 rb Cell signaling 
Rpt6 WB 1:500 ms Enzo lifescience 
GAPDH WB 1:2000 ms Abcam 
 




Table 4.2: List of secondary antibodies. 
Secondary antibody Application Conjugated probe Dilution Host Company 
anti-mouse IgG WB HRP 1:10000 goat Dianova 
anti-rabbit IgG WB HRP 1:10000 goat Dianova 
anti-mouse IgG ICC Cy2 / Alexa 488 1:1000 goat Dianova 
anti-rabbit IgG ICC Cy3 / Alexa 555 1:1000 goat Dianova 
 
4.1.4 Enzymes 
Enzymes used in this study are listed in Table 4.3. 
 
Table 4.3: List of enzimes. 
Enzyme Company 
Restriction Enzymes New England Biolabs 
Pfu DNA Polymerase Fermentas / Thermo Fisher Scientific 
T4 DNA Ligase Fermentas / Thermo Fisher Scientific 
GoTaq® DNA Polymerase Fermentas / Thermo Fisher Scientific 
Proteinase K AppliChem 
DNase I Roche 
Lambda Protein Phosphatase New England Biolabs 
 
4.1.5 Buffers and solutions 
 
10x PBS: 1.37 M NaCl, 14.7 mM KCl, 78.1 mM Na2HPO4, 26.8 mM KH2PO4, adjust to pH 7.4 
 
Molecular Biology: 
2x TAE: 80 mM Tris-acetate, 2 mM EDTA, adjust to pH 8.5 
2x YT medium (for 1 L): 5 g NaCl, 16 g tryptone, 10 g yeast extract 
2x YT agar plates: add 1.5 % agar and 50 μg/ml ampicillin or kanamycin 
 





SD (synthetic dropout) media and plates (for 500 ml): 3.35 g Yeast nitrogen base w/o amino 
acids, X g Drop out supplement {X = 0.69 g -Leu, 0.64 g -Leu/-Trp, 0.72 g -His, 0.62 g -Leu/-
Trp/-His} (Clontech), adjust pH to 5.8 and autoclave (for plates: add 10 g agar). After cooling, 
add 25 ml of 40 % glucose 
2x YPDA (for 250 ml): 10 g peptone, 5 g yeast extract, adjust pH to 6.5 and autoclave. After 
cooling, add 25 ml of 40 % glucose 
Z-buffer (for 1 L): 16.1 g Na2HPO4 x 7 H2O, 5.5 g NaH2PO4 x H2O, 0.75 g KCl, 0.246 g 
MgSO4 x 7 H2O, adjust pH to 7 and autoclave 
autoclave. After cooling, add 25 ml of 40 % glucose 
X-Gal stock: 20 mg/ml in dimethylformamide 
Z-buffer / X-GalX-Gal stock: 10 ml Z-buffer, 167 µl X-Gal stock, 27 µl ß- 
mercaptoethanol 
 
HEK293T cell culture 
HEK293T medium: DMEM [+] 4.5 g/L glucose [-] glutamine [-] pyruvate (GibcoTM), 10% FCS 
(HyClone), 1% GlutaMAX® (GibcoTM) 
1x TE (for 10 ml): 1 ml Trypsin-EDTA 0.5 % (GibcoTM), 1 ml 10x HBSS (GibcoTM), 8 ml H2O 
 
HEK293T and primary neuron culture transfection 
2x HBSS: 50 mM HEPES pH 7.05 - 7.11, 280 mM NaCl, 10 mM KCl, 15 mM glucose, 1.5 mM 
Na2HPO4 
Nucleofection plating medium: DMEM [+] 4.5 g/L glucose [-] L-glutamine [-] pyruvate 
(GibcoTM), 10% FCS (HyClone) 
 
Primary cortical neuron cell culture 
HHGN: 1x HBSS (Hank's Balanced Salt Solution), 2.5 mM HEPES pH 7.5, 35 mM glucose 
(GibcoTM), 4 mM NaHCO3 
TDn: 50 mg Trypsin (Worthington), 5 ml HHGN, 250 µl DNase (2µg/µl) 










BME / HS: BME [+] Earle's salts [-] L-glutamine (GibcoTM), 10 % horse serum (heat 
inactivated) 
8 % PFA: 375 ml H2O at 60°C, 50 ml 10x PBS, 40 g Paraformaldehyde, 40 g sucrose, adjust 
to pH 7.4, adjust volume to 500 ml with H2O 
Mounting medium: 12 ml 0.2 M pH 8.5 Tris-HCl, 6 g glycerol (85%), 2.4 g Mowiol 4-88 
(Calbiochem), 6 ml H2O, 2.5 % C6H12N2 (DABCO®) 
DAPI: 1 µg/µl stock, final concentration 1:8000 in H2O 
 
Common buffers for biochemistry 
TritonTM X-100 lysis buffer: 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 % TritonTM 
X-100 
Co-IP buffer:  20 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 % NonidetTM P-40, 10% 
glycerol  
RIPA buffer: 50 mM Tris-HCl pH 8.0, 150 mM NaCl, 5 mM EDTA, 0.5 % sodium 
deoxycholate, 1 % NonidetTM P-40, w/ or w/o 0.1 % SDS 
 
Subcellular fractionation 
Buffer A: 10 mM HEPES pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA 
Buffer A+: Buffer A, 0.1 % NonidetTM P-40 
Buffer C: 20 mM HEPES pH 7.9, 400 mM NaCl, 1 mM EDTA, 1 mM EGTA 
 
Cell-based ubiquitination assay 
UA-Lysis Buffer: 50 mM HEPES pH 7.5, 150 mM NaCl, 1.5 mM MgCl2, 1 % Triton
TM X-100, 
10 % glycerol 
HNTG buffer: 20 mM HEPES pH 7.5, 150 mM NaCl, 0.1 % TritonTM X-100, 10% glycerol 
 
Protein purification 
Resuspension / Lysis buffer: 20 mM Tris-HCl pH 7.5, 0.5 M NaCl, 0.025 % NonidetTM P-40, 1 
mM DTT, 20 mM Imidazole 








Proteasome affinity purification 
Proteasome lysis buffer C / Purification buffer: 25 mM Tris-HCl pH 7.5, 10 % glycerol, 5 mM 
MgCl2, 1 mM ATP, 1 mM DTT 
 
Proteasome assays 
Proteasome cell lysis buffer A: 50 mM Tris-HCl pH 7.5, 250 mM sucrose, 5 mM MgCl2, 2 mM 
ATP, 1 mM DTT, 0.5 mM EDTA, 0.025 % digitonin 
Proteasome cell lysis buffer B: 20 mM Tris-HCl pH 7.4, 5 mM MgCl2, 2 mM ATP, 1 mM EDTA 
Proteasome activity assay buffer: 50 mM Tris-HCl pH 7.5, 40 mM KCl, 5 mM MgCl2, 0.5 mM 
ATP, 1 mM DTT, 0.05 mg/ml BSA 
Native PAGE activity assay buffer: 50 mM Tris-HCl pH 7.4, 5 mM MgCl2, 1 mM ATP, w/ or 
w/o 0.02 % SDS 
Glycerol gradient buffer: 20 mM Tris-HCl pH 7.4, 5 mM MgCl2, 2 mM ATP, 1 mM DTT, 1 mM 
EDTA, 10 - 40 % glycerol 
 
SDS-PAGE 
Lower buffer: 1.5 M Tris-HCl pH 8.8, 0.4 % SDS 
Upper buffer: 0.5 M Tris-HCl pH 6.8, 0.4 % SDS 
Running buffer: 125 mM Tris, 1.25 M glycine, 0.5 % SDS 
Transfer buffer: 20 mM Tris, 153 mM glycine, 20 % methanol  
SDS-sample buffer: 300 mM Tris-HCl pH 6.8, 50 % glycerol, 10 % SDS, 25% β-
mercaptoethanol, 0.05% bromophenol blue  
PBST: 1x PBS, 0.1% Tween-20  
 
Native PAGE 
Native PAGE running buffer: 90 mM Tris base, 90 mM boric acid, 5 mM MgCl2, 0.5 mM 
EDTA, 0.5 mM ATP 
Native PAGE pre-transfer buffer: 25 mM Tris base, 192 mM glycine, 1 % SDS 
Native PAGE sample buffer: 125 mM Tris-HCl pH 6.8, 50 % glycerol, 2 % bromophenol blue 
 
Colloidal Coomassie staining 
Dye stock solution: 0.1 % w/v Coomassie Brilliant Blue G-250 (AppliChem), 2 % w/v ortho-
phosphoric acid, 10 % w/v ammonium sulfate 
Dye working solution: 80 % v/v Dye stock solution, 20 % v/v methanol 





Tail lysis buffer: 10 mM Tris pH 8.0, 200 mM NaCl, 10 mM EDTA, 0.5 % SDS 
 
Immunohistochemistry 
X-gal: 1 mg/ml X-gal in DMSO 
X-gal buffer: 2 mM MgCl2, 0.02% NP40, 0.01 % sodium deoxycholate, 5 mM potassium 
ferrocyanide, 5 mM potassium ferricyanide 
0.2 M Phosphate fixation buffer: 0.36 % w/v NaH2PO4, 3.1 % w/v Na2HPO4, 1 % w/v NaCl 
HCl/Alcohol:  1.25 ml concentrated HCl, 500 ml 70 % EtOH 
4 % PFA for paraffin IHC: 4 % w/v PFA, 0.1 M phosphate fixation buffer 
Citrate buffer: 1.8 mM C6H8O7 x H2O, 8.2 mM C6H5Na3O7 x 2 H2O, adjust to pH 6.0 
Tris buffer:  0.9 % w/v NaCl, 50 mM Tris-HCl pH 7.6 
BSA/PBS: 0.04 M NaH2PO4, 0.16 M Na2HPO4, 1.8 % w/v NaCl, 1 % w/v BSA 
Blocking buffer: 20 % goat serum v/v in BSA/PBS 
 
Anesthetics 
Ketamine/xylazine: 10 % ketamine v/v (10% Ketamine, Medistar, Arzneimttelveitrieb 
GmbH®), 5 % xylazine (2 % xylazine, CP Pharma®) 
 
4.1.6 Plasmid constructs and Primers 
A detailed list of plasmid constructs and primer sequences used in this study is 
attached as Appendix 1 and Appendix 2. 
 
4.2 Methods 
4.2.1 Molecular biology 
4.2.1.2 Expression plasmid cloning 
To generate expression plasmids encoding the gene of interest, appropriate primers 
were designed for subsequent amplification of the cDNA with PCR (Tables 4.4 and 4.5). The 
annealing temperature of the primers was set 5°C below the melting temperature of the 
respective primer. Elongation time was adjusted to the length gene of interest and the 
anticipated elongation rate of the Pfu polymerase of 500 bp / min. 




Table 4.4: PCR mix. 
Amount Reagent 
10 - 50 ng DNA template 
1 μl forward primer (10 pmol/μl) 
1 μl reverse primer (10 pmol/μl) 
0.4 μl dNTP (25 mM) 
0.5 μl Pfu DNA Polymerase (2.5 U/μl) 
5 μl 10x Pfu reaction buffer (+MgSO4) 
41.1 μl H2O 
 
 
Table 4.5: PCR program. 
Program step Temperature Time Repetitions 
Initial denaturation 95°C 3 min - 
Denaturation 95°C 30 sec 
 
30 cycles 
Annealing X°C 30 sec 
Elongation 72°C X min 
Final elongation 72°C 5 min - 
 
Following the PCR, amplificates were analyzed using 1 % agarose gel 
electrophoresis. DNA fragments of expected size were then excised, extracted from the gel 
using the NucleoSpin® gel clean-up kit and eluted in 20 μl H2O.  
Subsequently, the purified PCR product (insert) and 2 μg of the target expression 
vector were digested for 1 h at 37°C using restriction enzymes corresponding to the vector's 
multiple cloning site. After restriction digest, insert and vector were purified using the 
NucleoSpin® gel clean-up kit and eluted in 15 μl and 50 μl H2O, respectively. The ligation 
reaction was set up using 3 - 5 μl of insert combined with 1 μl of linearized and 
dephosphorylated vector and incubated overnight in icy water on the bench (Table 4.6).  
 




Table 4.6: Ligation mix. 
Amount Reagent 
1 μl Plasmid vector 
3.5 μl DNA insert 
0.6 μl ATP (10 mM) 
1 μl T4 DNA Ligase 
1 μl 10x T4 DNA Ligase Buffer 
2.9 μl H2O 
 
After overnight ligation, the full ligation reaction was used to transform 100 μl of the 
chemically competent E.coli strain DH5α. For transformation, bacteria were incubated 30 min 
on ice with the ligation reaction, followed by a 2 min heat shock at 37°C and a 1 min cool 
down on ice. Afterwards, 500 μl of 2x YT medium without antibiotics was added and the 
bacteria incubated for 30 min at 37°C. Finally, bacteria were spun down for 5 min at 4000 rpm 
and plated onto prewarmed 2x YT agar plates containing the antibiotic matching the vector-
encoded antibiotic resistance. Agar plates were incubated overnight at 37°C. To verify 
successful ligation of insert and vector, bacterial colonies were first picked and inoculated in 2 
ml 2x YT medium with antibiotic and incubated overnight at 37°C and 175 rpm. Then, plasmid 
DNA extraction from the bacterial culture was carried out using the NucleoSpin® plasmid 
quick pure kit. Extracted DNA was subjected to a restriction digest to identify positive clones. 
DNA from putatively positive clones was then submitted for sequencing to the AGCT Lab at 
the Max Planck Institute of Experimental Medicine, Göttingen. 
 
4.2.1.2 Deletion mutant cloning 
For the generation of a gene mutant lacking a given sequence or domain, two sets of 
primers were designed to carry out fusion PCR. The first set covers the sequence before to 
the domain to be deleted and includes 15 base pairs of the sequence right after the domain. 
The second set, in turn, covers 15 base pairs of the sequence before the domain and the 
sequence after the domain to the stop codon. The so generated PCR product thus has an 
overlapping stretch to support the annealing of the two fragments. The two sets of primers 
were then used to run two separate PCRs using 50 ng of template DNA under the previously 




mentioned conditions (Tables 4.4 and 4.5) resulting in the generation of two fragments of the 
gene, lacking the domain of interest. The partially overlapping fragments were then used as 
template DNA for a fusion PCR, using the start and the stop codon primers thereby 
generating a full-length version of the gene lacking the domain of interest. Generation of an 
expression plasmid containing the deletion mutant was then carried out as described above. 
 
4.2.1.3 Yeast Two-Hybrid library screening 
The yeast two-hybrid system was used to screen a cDNA library for potential 
interaction proteins of FBXO7. The method is based on the fusion of the Gal4 DNA-binding 
domain (Gal4-BD) to the bait and the Gal4 DNA-activation domain (Gal4-AD) to the prey 
protein resulting in the functional assembly of the Gal4 transcription factor only in case of 
interaction of the bait and the prey protein. Assembly of the Gal4 transcription factor then 
leads to the transactivation of selection genes, allowing the screening of a large library. The 
method was carried out according to the Matchmaker® Gold Yeast Two-Hybrid System User 
Manual (Clontech, US). 
Full-length FBXO7 was used as bait and cloned into the pGBT9-BD vector carrying 
the TRP1 nutritional marker. The tryptophane-auxotrophic yeast strain AH109 was used for 
bait construct transformation. As a first step, the bait construct and the AH109 yeast strain 
were tested for toxicity and autoactivation. To test for toxicity of the bait construct, AH109 
yeast was transformed with the pGBT9-BD-FBXO7 construct followed by plating on SD/-Trp 
and assessment of colony growth after 2 - 3 days incubation at 30°C. Autoactivation was 
assessed by transformation and growth on SD/-His plates.  
As prey, the Mate & PlateTM Library containing a human fetal brain cDNA library 
(Clontech, Cat. No. 630469) transformed into the leucine-auxotrophic yeast strain Y187 was 
used. To perform a control mating, one colony of each yeast strain grown on their respective 
selection plate was placed in a 1.5 ml reaction tube containing 2x YPDA and vortexed. 
Subsequently, the mixture was incubated for 24 h at 30°C and 200 rpm. The mated culture 
was then plated on SD/-Trp/-Leu plates and incubated at 30°C for 3 - 5 days.  
For the main culture of mating, a fresh bait strain colony was inoculated in 50 ml SD/-
Trp medium and incubated at 30°C and 250 rpm until OD600 = 0.8 (13h). Cells were then 
pelleted by centrifugation for 5 min at 1000 g and adjusted to a cell density of >1x108 cells / 
ml in a total of 5 ml SD/-Trp medium. Next, a 1 ml aliquot of the library strain was thawed out, 
10 μl removed and plated on SD/-Leu plates for library titer determination, and the rest used 




for mating. For mating, 1 ml of the Mate & Plate library was combined with 5 ml bait strain in a 
2 L flask containing 45 ml of 2x YPDA supplemented with 50 μg/ml kanamycin. The mating 
culture was then incubated for 24 h at 30°C and 50 rpm. Subsequently, cells were centrifuged 
for 10 min at 1000 g and resuspended with 100 ml of 0.5x YPDA supplemented with 50 μg/ml 
kanamycin. Following another centrifugation for 10 min at 1000 g, cells were resuspended in 
10 ml of 0.5x YPDA/Kan and 100 μl of the mated culture plated on SD/-Trp, SD/-Leu and 
SD/-Trp/-Leu plates to determine the mating efficiency. The remainder of the culture was then 
spread with 200 μl per 150 mm SD/-Trp/-Leu/-His plates and incubated at 30°C for 5 days. 
Specific colonies (>2 mm) were then picked and replica-plated on prewarmed SD/-Trp/-Leu/-
His plates. 
To eliminate false-positive clones, a ß-galactosidase assay was performed using one 
of the replica plate sets. For this, a nitrocellulose membrane was placed on the replica plate 
for 1 min and then dipped into liquid nitrogen for 30 sec. After 20 sec of thawing, the 
membrane was placed onto a Whatman paper soaked in Z-buffer / X-Gal solution and 
incubated for 30 min - 3 h at RT followed by identification of the ß-gal-producing clones. 
ß-gal-positive clones were then subjected to colony PCR (Tables 4.7 and 4.8) and 
submitted for sequencing to the AGCT Lab at the Max Planck Institute of Experimental 
Medicine, Göttingen. 
 
Table 4.7: Colony PCR mix. 
Amount Reagent 
 mix with pipette tip dipped in the colony 
1 μl forward primer 1596 (10 pmol/μl) 
1 μl reverse primer 1681 (10 pmol/μl) 
2.1 μl dNTP (2.5 mM) 
0.1 μl GoTaq® DNA Polymerase 
5 μl 5x GoTaq® reaction buffer 
10.8 μl H2O 
 
 




Table 4.8: Colony PCR program. 
Program step Temperature Time Repetitions 
Initial denaturation 95°C 3 min - 
Denaturation 95°C 30 sec 
 
30 cycles 
Annealing X°C 30 sec 
Elongation 72°C 5 min 
Final elongation 72°C 10 min - 
 
 
4.2.2 Cell culture and transfection 
Experimental work with cell cultures was carried out in a biological safety cabinet 
(HERAsafe®, Thermo Fisher Scientific). Cultured cells and cell lines were maintained in an 
incubator (HERAsafe®, Thermo Fisher Scientific) at 37°C with 5% CO2. 
 
4.2.2.1 HEK293T cell culture 
HEK293T cells were maintained in HEK293T medium on 10 cm culture dishes 
(Falcon®, Corning). Regular passaging was achieved by cell splitting at a confluency of 90 % 
by briefly rinsing the cells with 3 ml PBS, followed by incubation with 2 ml 1x TE for 5 min at 
37°C. Stopping of the trypsin digest and detachment of the cells from the cell culture dish was 
carried out by suspending the cells in 8 ml HEK293T medium. Subsequently, cells were 
collected and centrifuged for 5 min at 4°C and 800 rpm. The supernatant was then discarded 
and the cell pellet resuspended in fresh HEK293T medium. Resuspended cells were plated 
onto either 10 cm culture dishes at a dilution of 0.5 - 2 ml cell suspension in 8 ml HEK293T 
medium or onto 6-well plates (CELLSTAR®, Greiner Bio-One) at a dilution of 200 μl cell 
suspension in 2 ml HEK293T medium.  
 
4.2.2.2 Transfection of HEK293T cells 
HEK293T cell transfection was carried out using an adapted version of the calcium 
phosphate method described in (Konishi et al., 2004).  




Cells were split onto 6-well plates the day before and transfected once the cells 
reached a confluency of 80 %. For each 6-well, 0.01 - 3 µg of plasmid DNA was diluted in 90 
µl of H2O, followed by addition of 10 µl of 2.5 M CaCl2 and 100 µl of 2x HBSS. Subsequently, 
the DNA calcium phosphate solution was pipetted up and down to ensure proper mixing and 
incubated 5 min at RT. Finally, the entire DNA mix was added to the 6-well and incubated 
with the cells 48 and 96 h prior to lysis for overexpression and knockdown plasmids, 
respectively. 
 
4.2.2.3 Primary cortical neuron culture 
Cortices from P0 Wistar rats were isolated in 1x HBSS (Hank's Balanced Salt 
Solution) and separated from meninges as well as the hippocampus. Following three washes 
with 1x HBSS, cortices were incubated with 5 ml of TDn for 10 min at 37°C. To stop the 
trypsin digest, cortices were washed three times with 1x HBSS and subsequently triturated in 
5 ml of cortical neuron plating medium with 250 µl of freshly added DNase (2 mg/ml). The cell 
suspension was then centrifuged for 5 min at 4°C and 800 rpm and the pellet resuspended in 
20 ml of cortical neuron plating medium. Plates and 12 mm coverslips were coated with 
polyornithine for at least 30 min at 37°C followed by two washes with H2O and drying at 37°C. 
Cell titer was determined using a hemocytometer. 0.2 - 0.3 x 106 cells were plated per 24-well 
and 6 - 10 x 106 per 6-well. 
 
4.2.2.4 Transfection of primary cortical neurons 
Primary cortical neurons grown on 12 mm coverslips in a 24-well plate were 
transfected at day in vitro (DIV) 1 for overexpression analysis and at DIV3 for survival assays 
using a modified version of the previously described calcium phosphate transfection method. 
First, the conditioned culture medium was collected, stored at 37°C and replaced with 
prewarmed 1x DMEM ( [+] 4.5 g/L glucose [-] L-glutamine [-] pyruvate (GibcoTM) ). After one 
wash with 1x DMEM, neurons were starved in 500 µl 1x DMEM for 30 - 45 min at 37°C. In the 
meanwhile, 0.02 - 3 µg of plasmid DNA was diluted in 18 µl of H2O, followed by addition of 2 
µl of 2.5 M CaCl2 and 20 µl of 2x HBSS. Subsequently, the DNA calcium phosphate solution 
was pipetted up and down to ensure proper mixing and incubated 5 min at RT. The entire 
DNA mix was then added to the 24-well and incubated with the neurons for 14 - 18 min at 
37°C. Finally, neurons were washed twice with 1x DMEM before the stored conditioned 
medium was returned. 




4.2.2.5 Nucleofection of primary cortical neurons 
Following the primary cortical neuron culture, 8 x 106 rat cortical neurons were 
resuspended in 100 µl of 1x DMEM and 7 - 10 µg plasmid DNA added. The DNA-cell 
suspension was then subjected to electrical pulsing using the O-005 program of the 
nucleofector (Amaxa®, Lonza) and incubated with 1 ml of prewarmed 1x DMEM for 5 min at 
RT. Finally, neurons were plated onto polyornithine-coated 6-well plates with prewarmed 




Cortical neuron cultures subjected to survival assays were fixed with 8 % PFA, which 
was directly added to the conditioned medium to a final concentration of 4 % and incubated 
for 10 min at RT. Cells for morphological analyses were washed twice with PBS and then 
fixed with 4 % PFA for 10 min at RT. Following fixation, cells were washed twice with PBS 
and then permeabilized with 0.04 % TritonTM X-100 in PBS for 10 min at RT. After two more 
washes with PBS, cells were blocked using BME / HS for 30 min at RT. The primary antibody 
was diluted and applied in BME / HS and incubated for either 1 h at RT or overnight at 4°C. 
Subsequently, cells were washed twice with BME / HS and then incubated with the 
secondary antibody diluted in BME / HS for 30 min at RT. Following two washes with PBS, 
the cells were incubated with the DNA dye DAPI (4’6-diamidino-2-phenylindole) for 10 min at 
RT, then rinsed twice more with PBS and finally mounted using mounting medium on 
microscope slides (Marienfeld). 
 
4.2.2.7 Survival assay in primary cortical neurons 
The survival assay was carried out using an adapted version of the method described 
in (Becker and Bonni, 2004). Cortical neurons plated on 12 mm coverslips were transfected 
at DIV3 with 0.05 - 0.2 µg GFP, serving as a transfection marker along with the respective 
plasmids of interest. At DIV7, neurons were subjected to immunocytochemical staining using 
the GFP and the cleaved caspase-3 antibodies along with the DNA dye DAPI. GFP-positive 
neurons were examined for their viability status based on integrity of neurites, nuclear 
morphology and the apoptotic marker cleaved caspase-3. Analyses were carried out in a 
blinded manner and approximately 100 cells were analyzed per condition. 
 




4.2.3 FBXO7 knockout mice 
4.2.3.1 Generation of FBXO7 knockout mice 
The generation of FBXO7 conventional knockout mice was achieved using ES cells 
purchased from the International Knockout Mouse Consortium (EUCOMM ID: 23037). ES 
cells were injected into C57BL/6N blastocysts, implanted into a female foster mouse and the 
resulting chimeras crossed to C57BL/6N mice to achieve germline transmission.  
 
4.2.3.2 Isolation of genomic DNA 
To isolate DNA for genotyping, mouse tail biopsies were digested for 3 h or overnight 
at 55°C in 200 µl of Tail lysis buffer freshly supplemented with 3 µl proteinase K (200 µg/ml). 
After resuspension of the digested tails by agitation of the tube, samples were centrifuged for 
7 min at 14000 rpm. The supernatant was then transferred into a new tube and the DNA 
precipitated using 2.5 volumes of 100 % EtOH. DNA pellets were washed twice with 70 % 
EtOH and subsequently air-dried prior to addition of 100 µl of H2O. 
 
4.2.3.3 Genotyping of FBXO7 knockout mice 
Two separate PCR reactions (Tables 4.9 and 4.10) were set up to achieve 
genotyping of FBXO7 mice determining presence or absence of the FBXO7 gene or the lacZ 
reporter cassette, respectively. 
 
Table 4.9: Genotyping PCR mix. 
Amount Reagent 
100 ng (0.5 μl) DNA 
1 μl forward primer (10 pmol/μl) 
1 μl reverse primer (10 pmol/μl) 
2.1 μl dNTP (2.5 mM) 
0.1 μl GoTaq® DNA Polymerase 
5 μl 5x GoTaq® reaction buffer 
10.3 μl H2O 
 




Table 4.10: Genotyping PCR program. 
Program step Temperature Time Repetitions 
Initial denaturation 95°C 3 min - 
Denaturation 95°C 30 sec 
 
28 cycles 
Annealing 51°C 30 sec 
Elongation 72°C 2 min 
Final elongation 72°C 10 min - 
 
4.2.4 General biochemical methods 
4.2.4.1 Tissue lysate preparation 
Mice were sacrificed by CO2 inhalation or cervical dislocation. For general analysis, 
the isolated tissue of interest was lysed in TritonTM X-100 lysis buffer freshly supplemented 
with protease, phosphatase and in case of ubiquitin-dependent processes also 
deubiquitination enzyme inhibitors (3 µg/ml aprotinin, 1 µg/µl leupeptin, 1 µg/µl pepstatin, 1 
mM DTT; 0.5 mM NaVO3, 1 mM NaF; 10 mM N-ethylmaleimide (NEM)). Tissue lysis and 
homogenization was carried out with a 2 ml dounce (KONTES®) followed by incubation on 
ice for 30 min. Subsequently, lysates were centrifuged for 10 min at 4°C and 14000 rpm, the 
supernatant collected in a fresh tube and either directly used for analysis or snap frozen using 
liquid nitrogen and stored at -80°C. 
 
4.2.4.2 Cell lysate preparation 
HEK293T or primary neuronal cells were first washed once with PBS, followed by 
addition of TritonTM X-100 lysis buffer or co-IP buffer freshly supplemented with protease, 
phosphatase and in case of ubiquitin-dependent processes also deubiquitination enzyme 
inhibitors. Subsequently, adherent cells were scraped off the plate surface using a cell 
scraper (Greiner Bio-One) and incubated on ice for 30 min. Subsequently, lysates were 
centrifuged for 10 min at 4°C and 14000 rpm, the supernatant collected in a fresh tube and 
either directly used for analysis or snap frozen using liquid nitrogen and stored at -80°C. 
 




4.2.4.3 Protein concentration determination 
Protein concentration determination of cell or tissue lysates was done using the Bio-
Rad Protein Assay, which is based on the method of Bradford (Bradford, 1976). The reagent 
was diluted 1:5 in ddH2O and pipetted into cuvettes (Greiner Bio-One). Subsequently, 1, 3, 5 
and 10 µg BSA were added to the mixture serving as a standard curve as well as 1 - 2 µl of 
the respective lysate of interest followed by vortexing and incubation for 5 min at RT. The 
absorbance at wavelength 595 nm was read using a spectrophotometer and the protein 
concentration calculated according to the BSA standard curve. 
 
4.2.4.4 Co-immunoprecipitation (co-IP) 
1 - 2 mg of cell lysates from transfected HEK293T cells were incubated with the 
primary antibody on a rotator for 3 h at 4°C. If different conditions varied in volume, co-IP 
buffer was used to equalize them. Subsequently, 10 - 30 µl of Protein A-sepharose bead 
slurry (Protein A-SepharoseTM Fast Flow, GE Healthcare), prewashed and maintained in co-
IP buffer, was added to the samples and incubated for another 45 - 60 min at 4°C on the 
rotator. Next, the samples were centrifuged for 30 sec at 7500 rpm, the supernatant 
discarded and the beads washed thrice with TritonTM X-100 lysis buffer followed by one wash 
with PBS. Finally, the PBS supernatant was removed except for approximately 20 µl, 
supplemented with 30 µl of SDS-sample buffer and boiled for 5 min at 95°C. 50 - 100 µg of 
the original cell lysate served as an input control. 
 
4.2.4.5 Subcellular fractionation 
Cortical tissue was lysed in Buffer A supplemented with protease inhibitors using a 2 
ml dounce. Next, lysates were centrifuged for 5 min at 4°C and 2000 rpm, the supernatant  
collected (S1) and spun down again for 5 min at 4°C and 2000 rpm. The resulting 
supernatant served as the cytoplasmic fraction. The pellets were washed 6 times with Buffer 
A+ and then resuspended in 100 µl Buffer C followed by centrifugation for 20 min at at 4°C 
and 14000 rpm. The resulting supernatant was harvested as the nuclear fraction. 
 
4.2.4.6 Cell-based ubiquitination assay 
The cell-based ubiquitination assay was carried out using an adapted version of the 
method described in (Lu et al., 2007). Transfected HEK293T cells were lysed in RIPA buffer 




without SDS supplemented with protease inhibitors and 10 mM NEM. Next, 1 - 2 mg of cell 
lysate were incubated with 1 % SDS for 5 min at 4°C on a rotator followed by boiling for 10 
min at 95°C to disrupt protein-protein interactions. The SDS concentration was then reduced 
to 0.1 % by mixing with UA-Lysis Buffer. Subsequently, primary antibody added and 
incubated overnight at 4°C on a rotator. For immunoprecipitation, Protein A-sepharose bead 
slurry was added and incubated with the samples for 45 min at 4°C on a rotator. Finally, 
beads were washed twice with UA-Lysis Buffer, once with RIPA containing SDS and once 
with PBS, followed by addition of 30 µl of SDS-sample buffer and boiling for 5 min at 95°C. 50 
- 100 µg of the original cell lysate served as an input control. 
 
4.2.4.7 SDS-PAGE and western blot 
SDS-PAGE gels were cast using the Mini-PROTEAN® Tetra Electrophoresis System 
from Bio-Rad. A standard gel consisted of an upper, so-called stacking gel containing 3.9 % 
acrylamide, and a lower, so-called separating gel containing 7.5 - 12 % acrylamide depending 
on the size of the proteins of interest. The composition of the stacking and separating gels is 
indicated in Table 4.11. 
 
Table 4.11: of gels used for SDS-PAGE. 
Reagent Separating gel Stacking gel 
Acrylamide 7.5 % 8 % 10 % 12 % 3.9 % 
ml Acrylamide (30 % stock) 1.875 2 2.5 3 0.65 
ml Lower Buffer 1.875 1.875 1.875 1.875 1.25 ml Upper Buffer 
ml H2O 3.75 3.625 3.125 2.625 3.05 
µl 10 % APS 75 49.5 
µl TEMED 7.5 4.95 
 
The separating gel reagents were mixed, poured into the gel casting setup and 
overlaid with a thin layer of isopropanol. After gel polymerization for 10 - 20 min, isopropanol 
was removed with H2O followed by addition of the stacking gel solution, insertion of a 10-well 
comb and polymerization for another 15 min.  




Boiled SDS sample buffer-added protein samples were loaded into the Running 
buffer-immersed gel wells along with a protein ladder marker and resolved at 25 - 35 mA per 
gel. Following electrophoresis, the SDS-gel was placed onto a nitrocellulose membrane 
(AmershamTM ProtranTM) and the proteins transferred using the Mini Trans-Blot® cell from 
Bio-Rad in cooled Transfer Buffer for 110 min at 230 mA. Nitrocellulose membranes were 
then blocked for 30 min using 4 % milk in PBST followed by three 10 min PBST washes. 
Subsequently, the membrane was incubated for 1 h at RT or overnight at 4°C with the 
primary antibody diluted in 3 % BSA or 4 % milk in PBS supplemented with 0.02 % NaN3. 
Following primary antibody incubation the membranes were washed three times for 10 min 
with PBST and then subjected to incubation for 30 min at RT with an HRP-coupled secondary 
antibody diluted in 4 % milk blocking solution. Subsequently, membranes were washed 
another three times for 10 min with PBST prior to incubation with an enhanced 
chemiluminescent (ECL) solution from a peroxidase substrate kit (PierceTM, Thermo Fisher 
Scientific). Finally, photographic films (Amersham HyperfilmTM ECL) and an automatic film 
developer machine (Curix 60, Agfa) were used to visualize the protein bands. 
 
4.2.4.8 Colloidal Coomassie staining 
Colloidal Coomassie staining was carried out according to Dörte Hesse's adapted 
protocol from (Neuhoff et al., 1988). SDS-PAGE gels were fixed with 40 % v/v EtOH, 10 % 
v/v acetic acid for at least 60 min at RT. After two washes with H2O for 10 min, the gels were 
incubated in Dye working solution for 60 min or overnight at RT. Subsequently, the gels were 
washed with 1 % acetic acid until all Coomassie particles were removed. 
 
4.2.5 Proteasome biochemistry 
4.2.5.1 Measurement of proteasome activity from lysates 
The lysate proteasome activity assay was carried out using an adapted version of the 
method described in (Kisselev and Goldberg, 2005). Transfected HEK293T cells or tissue 
were lysed and homogenized in the non-detergent-based Proteasome cell lysis buffer A to 
prevent dissociation of the proteasome holocomplexes and then centrifuged for 10 min at 4°C 
and 14000 rpm. Subsequently, 12 µg of tissue or cell lysate was pipetted in triplicates into a 
96-well plate containing Proteasome activity assay buffer and incubated for 5 min at 37°C. 
Next, 100 µM of the fluorogenic peptide substrate Suc-LLVY-AMC was added to the wells, 




mixed and fluorescence measured at 0, 30, 60, 90 min using a fluorescent plate reader (355 
nm excitation and 460 nm emission). To verify comparable lysate loading amounts, genotype 
or successful transfection, 50 µg of the respective lysate was subjected to western blot. 
 
4.2.5.2 Characterization of proteasome profiles using native PAGE 
Native PAGE gels were cast using the Mini-PROTEAN® Tetra Electrophoresis 
System from Bio-Rad. The gels consisted of a stacking gel containing 2.75 % acrylamide, 
and a separating gel containing 3.75 %. The composition of the stacking and separating gels 
is indicated in Table 4.12. 
 
Table 4.12: Composition of gels used for Native PAGE. 
Reagent Separating gel Stacking gel 
400 mM Tris base/Boric acid 1.5 ml 0.6 ml 
1 M MgCl2 37.5 µl 15 µl 
500 mM EDTA 7.5 µl 3 µl 
400 mM ATP 18.75 µl 7.5 µl 
Acrylamide (30 %) 937.5 µl 275 µl 
H2O 4.98 ml 2.1 ml 
APS (10 %) 75 µl 30 µl 
TEMED 7.5 µl 3 µl 
 
The separating gel reagents were mixed, poured into the gel casting setup and 
overlaid with a thin layer of isopropanol. After gel polymerization for 10 - 20 min, isopropanol 
was removed with H2O followed by addition of the stacking gel solution, insertion of a 10-well 
comb and polymerization for another 15 min. Gels were then placed into a running chamber 
placed on ice and filled with cold Native PAGE running buffer.  
25 - 75 µg of cell or tissue lysates prepared in Proteasome cell lysis buffer A or 25 µg 
of purified 26S proteasomes were mixed with Native PAGE sample buffer and loaded into the 
gel well. Next, the gels were resolved for 125 min at 175 V and afterwards immersed in 
Native PAGE activity assay buffer. Following addition of 100 µM of Suc-LLVY-AMC, the gel 
was incubated for 10 min at 37°C and the proteasome profile visualized by exposure to UV 




light. For stimulation of the latent 20S proteasome activity, 0.02 % SDS was added and the 
gel incubated for another 10 min at 37°C. Subsequently, the gel was immersed in Native 
PAGE pre-transfer buffer and incubated for 10 min at RT. Finally, the gel was placed onto a 
nitrocellulose membrane (AmershamTM ProtranTM) and the proteins transferred using the Mini 
Trans-Blot® cell from Bio-Rad in cooled Transfer Buffer for 110 min at 230 mA. Western blot 
was then carried out to confirm the proteasome content in the gels.  
 
4.2.5.3 Glycerol density gradient centrifugation and analysis of proteasome fractions 
Glycerol density gradient centrifugation was carried out using an adapted version of 
the method described in (Koulich et al., 2008). Transfected HEK293T cells or tissue were 
lysed and homogenized in Proteasome cell lysis buffer B and then centrifuged for 10 min at 
4°C and 14000 rpm. Per condition, a total amount of 0.5 - 1.5 mg of lysate was used. Linear 
glycerol gradients containing 10, 20, 30 and 40 % glycerol were prepared in a total volume of 
4 ml using Glycerol gradient buffer followed by loading of the sample on top. Subsequently, 
samples were centrifuged for 14 h at 4°C and 83000 g using a Beckman XL-90 
ultracentrifuge with a SW-60 Ti rotor (Beckman Coulter). Following centrifugation, the 
gradients were pipetted off into 20 fractions with a volume of 200 - 220 µl. Per fraction, 20 µl 
were subjected to proteasome activity measurement as described in section 4.2.5.1. The 
remaining fraction was precipitated using a 4x volume of icecold acetone. Following an 
incubation time of 60 min at -20°C, the samples were centriuged for 10 min at 14000 rpm and 
the supernatant discarded. The pellets were air-dried for 30 min prior to addition of SDS-
sample buffer and boiling for 5 min at 95°C. SDS-PAGE and western blot were then carried 
out to confirm protein and proteasome content in each fraction.  
 
4.2.5.4 Proteasome affinity purification 
Proteasome affinity purification was carried out using an adapted version of the 
method described in (Besche and Goldberg, 2012). In this protocol, the GST-tagged Ubl-
domain of RAD23B is used to bind and precipitate 26S proteasomes with high affinity. In a 
second step, the His10-tagged UIM-domain of S5a is used for elution of 26S proteasomes by 
binding competition for the RAD23B Ubl-domain.  
GST-UblRAD23B was previously generated in the lab. To bacterially express and purify 
His10-UIM
S5a, the UIMS5a cDNA was cloned into the bacterial expression vector pET28a. For 
transformation of BL21 bacteria, 50 ng of plasmid was used followed by plating on 




kanamycin-containing 2x YT agar plates and overnight growth at 37°C. Next, a preculture of 
12 ml 2x YT with kanamycin was inoculated with a bacterial colony and grown overnight at 
37°C and 175 rpm. 10 ml of the preculture was then used to adjust the main bacterial culture 
of 300 ml 2x YT and kanamycin to an OD600 = 0.1. The main culture was then grown at 37°C 
and 175 rpm up to an OD600 = 0.6 and induced using 0.5 mM Isopropyl β-D-1-
thiogalactopyranoside (IPTG). At an OD600 = 1.0 the bacterial culture was spun down for 30 
min at 4°C and 4000 rpm and resuspended in Resuspension / Lysis buffer freshly 
supplemented with protease inhibitors (3 µg/ml aprotinin, 1 µg/µl leupeptin, 1 µg/µl pepstatin, 
150 µM phenylmethanesulfonylfluoride (PMSF)). Subsequently, the samples were sonicated 
three times at 30 % power for 30 sec (SONOPULS UW 2070, Bandelin) followed by 
centrifugation for 20 min at 4°C and 10000 g. The supernatant was then added with 800 µl Ni-
NTA sepharose bead slurry (Ni-NTA Sepharose®, iba lifesciences) and incubated overnight 
at 4°C on a rotator. The beads were then spun down for 1 min at 4°C and 1000 g followed by 
one wash of 20x bead volume Resuspension buffer and another wash of 10x bead volume 
Resuspension buffer with 40 mM imidazole. Elution was achieved by incubation of the beads 
with Resuspension buffer with 500 mM imidazole overnight at 4°C on a rotator. Finally, the 
eluted fraction was dialyzed twice overnight at 4°C in Dialysis buffer and the purification 
verified by SDS-PAGE and Coomassie blue staining. 
For 26S proteasome affinity purification, 750 mg of cortical tissue pooled from four 
P18 FBXO7+/+ and -/- mice, respectively, was lysed in Proteasome lysis buffer C / 
Purification buffer using a mechanical homogenizer (POLYTRON®, PT 1200 E). Following 
the centrifugation of the cortical lysates for 20 min at 4°C and 14000 rpm, 750 µg of GST- 
UblRAD23B and 230 µl GST-bead slurry (Glutathione SepharoseTM 4B, GE Healthcare) were 
added to the lysates and incubated for 2.5 h at 4°C on a rotator. Subsequently, the beads 
were washed twice with 40x bead volume Purification buffer prior to the first elution by 
addition of 750 µg of His10-UIM
S5a. After mixing of the resin by pipetting and incubation for 15 
min at 4°C, the beads were spun down. A second elution was then performed by addition of 
750 µg of His10-UIM
S5a. The eluates 1 and 2 were then combined and incubated with 112.5 µl 
Ni-NTA sepharose bead slurry for 30 min at 4°C on a rotator. Following centrifugation for 1.5 
min at 4°C and 500 rpm, the supernatant was collected as the 26S proteasome elution 
fraction. Purity of the 26S proteasome eluates was determined by SDS-PAGE and 
Coomassie blue staining. Purified proteasomes were subjected to further analysis by native 
PAGE and proteasome activity assays. 
 




4.2.6 Histological analysis of mouse brain tissue 
4.2.6.1 Transcardial perfusion and fixation 
Mice were anesthetized by intraperitoneal injection of Ketamine/xylazine. Successful 
anesthesia was assessed by testing twitching reflexes due to pinching of the hind limbs. 
Subsequently, animals were stabilized on their dorsal side and the abdomen opened using 
dissection scissors and forceps. Upon removal of the diaphragm, a small butterfly canula 
(Venoflix®, Braun) attached to a peristaltic pump (HeidolphTM PD 5001, Thermo Fisher 
Scientific) was inserted into the left ventricle with simultaneous incision making on the right 
atrium. The blood was then flushed out using PBS, followed by fixation with 4 % PFA (diluted 
from 8 % PFA with PBS) for tissue destined for vibratome sectioning or 4 % PFA for paraffin 
IHC for tissue destined for microtome sectioning. The tissues of interest were then harvested 
and further processed by postfixation. For vibratome sectioning, tissues were postfixed in 4 % 
PFA for 4 h at 4°C, washed once in PBS followed by incubation in a 30 % sucrose solution 
overnight at 4°C. For Microtome sectioning, tissues were postfixed in 4 % PFA for paraffin 
IHC overnight at 4°C. 
 
4.2.6.2 X-Gal staining of vibratome mouse brain sections 
40 µm thick sagittal whole brain sections of P18 FBXO7 +/+ and FBXO7 -/- mice were 
obtained by vibratome sectioning (VT100S, Leica), collected in PBS and stored in PBS wit 
0.02 % NaN3 at 4°C until further processing. Free floating sections were then incubated under 
the exclusion of light overnight at 37°C in X-gal buffer with freshly added X-Gal. 
Subsequently, sections were washed in PBS and mounted onto microscope slides 
(Marienfeld), air-dried and mounted in 50 % glycerol. Finally, sections were imaged using a 
brightfield microscope (Axio Observer Z1, Zeiss) and the Zen 2011 imaging software (Zeiss, 
Germany). 
 
4.2.6.3 Microtome tissue embedding and sectioning  
Tissue destined for microtome sectioning was embedded in paraffin (Paraplast®, 
Leica) using an automated tissue processor (HMP110, MICROM) program listed in Table 
4.13.  
 




Table 4.13: of the automated tissue processor. 
Program step Time 
50 % v/v EtOH 1 h 
70 % v/v EtOH 2 x 2 h 
96 % v/v EtOH 2 x 2 h 
100 % v/v EtOH 2 x 2 h 
Isopropanol 1 h 
Xylol 2 x 2 h 
Paraffin 2 x 2 h 
 
 
Subsequently, brains were positioned in metal molds, embedded in 60°C warm 
paraffin and solidified by cooling. Paraffin blocks were then stored at RT until microtome 
sectioning (HM 430, Thermo Fisher Scientific) of 5 µm thick whole brain sagittal or coronal 
sections of P18 FBXO7+/+ and FBXO7-/- mice. Sections obtained with the sliding microtome 
were collected and transferred into a waterbath heated to 40°C (HIR-3, Kunz Instruments), 
mounted on microscopy slides (Marienfeld) and then air-dried at RT. 
 
4.2.6.4 Immunohistochemical staining of paraffin-embedded sections 
Mounted 5 µm thick sections were first subjected to a series of deparaffinization and 
rehydration steps. For this, sections were incubated for 10 min at 60°C to soften up the 
paraffin. Paraffin removal was then achieved by two 10 min incubations in Xylol and one 10 
min incubation in Xylol/Isopropanol (1:2). Subsequently, a series of rehydration steps was 
carried out by 5 min incubation in 100 %, 90 %, 70 % and 50 % v/v EtOH, respectively, 
concluded by a 5 min incubation in ddH2O. Subsequently, sections were incubated for 5 min 
in Citrate buffer followed by boiling for 10 min at 650 watts in a microwave for antigen 
retrieval. Afterwards, sections were cooled down at RT for 30 min and rinsed in Tris buffer 
with 2 % w/v milk powder prior to placement into ShandonTM coverplates (Thermo Fisher 
Scientific). Following another rinse in Tris buffer with 2 % w/v milk powder, endogenous 
peroxidase activity was inhibited by treatment with 3 % H2O2 for 5 min and washing in Tris 
buffer with 2 % w/v milk powder. Sections were blocked by incubation with Blocking buffer for 




10 min at RT and subsequently incubated overnight at 4°C in primary antibody diluted in 
BSA/PBS. The next day, sections were rinsed with Tris buffer with 2 % w/v milk powder and 
subjected to staining using the LSAB2 kit (Dako). For this, the slides were first incubated with 
a biotinylated secondary antibody solution for 10 min, followed by a rinse with Tris buffer with 
2 % w/v milk powder. Then, slides were incubated for 10 min with peroxidase-labelled 
streptavidin and rinsed with Tris buffer. Coverplates were then dismantled and the slides 
incubated for 5 - 10 min with the HRP substrate chromogen 3-3'-diaminobenzidine (DAB, 
Dako) resulting in brown-colored precipitates at the sites of antigen localization. Following 
DAB labelling, the slides were subjected to nuclear staining by rinsing twice in ddH2O prior to 
incubation in 0.1 % haematoxylin w/v (Merck) for 15 - 30 sec. Subsequently, sections were 
rinsed in ddH2O, developed by dipping in HCl/Alcohol and incubated for 5 min with the 
blueing agent Scott's solution (Thermo Fisher Scientific). After rinsing the slides once more 
with ddH2O a series of dehydration steps was carried out by 5 min incubations in 50 %, 70 %, 
90 % and 100 % v/v EtOH followed by 10 min incubations in Xylol/Isopropanol (1:2), Xylol 
and Xylol, respectively. Finally, samples were coverslipped using Eukitt® (Friedrichs et al.) 
mounting medium. Image acquisition was done using a brightfield microscope (Axio Observer 
Z1, Zeiss) and the Zen 2011 imaging software (Zeiss, Germany). 
 
4.2.6.5 Labelling of apoptotic cells using the TUNEL assay 
Mounted 5 µm thick sections were subjected to the TUNEL assay following the 
instructions of the commercially available DeadEnd™ Colorimetric TUNEL System kit 
(Promega). The assay is based on labelling of fragmented DNA by detection of biotinylated 
nucleotides at 3'-OH DNA sites incorporated by the terminal deoxynucleotidyl transferase 
(TdT) enzyme. Samples were coverslipped using Aqua-Poly/Mount (Polysciences) mounting 
medium. Image acquisition was done using a brightfield microscope (Axio Observer Z1, 
Zeiss) and the Zen 2011 imaging software (Zeiss, Germany). 
 
4.2.6.6 Area quantification of DAB stainings 
Area quantification of GFAP- or Iba1-positive areas was achieved using a custom-
designed imageJ macro provided by Dr. Miso Mitkovski. The macro functions by converting 
the picture into a black and white image, representing DAB-positive areas as black followed 
by measuring of the percentage area covered by the DAB signal as compared to the total 
area of interest selected. The detailed script is given below: (Trapp et al., 1998). 








run("Set Scale...", "distance=0 known=0 pixel=1 unit=pixel"); 
setTool("polygon"); 
beep();                                               
waitForUser("Hi there", "Select the region of interest and click OK"); 
run("Add to Manager"); 
//// 
// Color Thresholder 1.45k 























  selectWindow(""+i); 
  setThreshold(min[i], max[i]); 
  run("Convert to Mask"); 




  if (filter[i]=="stop")  run("Invert"); 
} 
imageCalculator("AND create", "0","1"); 
imageCalculator("AND create", "Result of 0","2"); 
for (i=0;i<3;i++){ 
  selectWindow(""+i); 
  close(); 
} 
selectWindow("Result of 0"); 
close(); 
selectWindow("Result of Result of 0"); 
rename(a); 
// Colour Thresholding------------- 
///// 










Quantification and analysis was performed in a blinded manner using at least three 
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List of plasmid constructs used in this study along with respective identification 
numbers, if applicable: 
 
Table A: List of plasmids. 
Vector plasmid Constructed by Primer numbers 
pEGFP-C1-FBXO7 Madhuvanthi Kannan 15222, 15223 
pSUPER-shFBXO7 #1 Siv Vingill A 
pSUPER-shFBXO7 #4 Siv Vingill B 
pCMV-myc-FBXO7 WT Madhuvanthi Kannan 15222, 15223 
pCMV-myc-FBXO7 T22M Siv Vingill 23795, 23796 
pCMV-myc FBXO7 M115I Siv Vingill 23797, 23798 
pCMV-myc-FBXO7 R378G Siv Vingill 23799, 23800 
pCMV-myc-FBXO7 R498X Siv Vingill 23801, 23802 
pCMV-myc-FBXO7 NT Siv Vingill 15223, 28045 
pCMV-myc-FBXO7 Ubl Siv Vingill 29150-2, 25771 
pCMV-myc-FBXO7 FP Siv Vingill 28506, 28507 
pCMV-myc-FBXO7 CT Siv Vingill 15222, 25771 
pCMV-myc-FBXO7 Fbox Siv Vingill 28504, 28505 
pCMV-myc-FBXO7 PRR Siv Vingill 28044, 25771 
pEGFP-C1-PSMA2 David Brockelt 30490, 28647 
p3xFLAG-CMV-10-PSMA2 David Brockelt 29139, 28647 
pCMV10-3xFLAG-LC1 WT David Brockelt 28482, 28646 
pCMV10-3xFLAG-LC1 MTB David Brockelt 28482, 28927 







David Brockelt 28482, 28930, 28929, 28646 
pCMV10-3xFLAG-LC2 David Brockelt 29441, 29442 
pCMV10-3xFLAG-MAP1S David Brockelt 29439, 29440 
pET-28a-UIM2
S5a
 David Brockelt 33589, 33590 
pGEX-Ubl
RAD23B
 David Brockelt 31340, 31341 
pGBT9-FBXO7 David Brockelt 25769, 25771 
pCMV-myc-FBXO31 
Dr. Raman Kumar, Prof. David 
Callen 
University of Adelaide, 
Australia 
pRK HA Ub WT Hiroshi Kawabe MPI-EM, Göttingen 
pRK HA Ub K63R Hiroshi Kawabe MPI-EM, Göttingen 





List of primer sequences used in this study along with respective identification 
numbers, if applicable: 
 
Table B: List of primers. 













































LacZ fwd ATTCCAGCTGAGCGCCGGTCGC 















AAA-ATPase ATPases Associated with diverse cellular Activities 
AD  Activator domain  
APP  
APS 
Amyloid precursor protein 
Ammonium persulfate 
ATP  Adenosine triphosphate 
ATP13A2 ATPase type 13A2 
ATPas Adenylpyrophosphatase 
β-Gal  β-Galactosidase 
bp Basepairs 
BME  Basal Medium Eagle  
BSA  Bovine serum albumin 
Cdk6  Cell division protein kinase 6 
cDNA complementary DNA 
cIAP1 Cellular inhibitor of apoptosis 1 
cm Centimeter 
CNS  Central nervous system 
Co-IP  Co-Immunoprecipitation 
CP  Core particle  
CT  C-terminus 
Cy Cyanine 
DAB  3-3’-diaminobenzidine  
DAPI  4’6-diamidino-2-phenylindole 
DIV  Days in vitro 
DMEM  Dulbecco’s modified Eagle’s medium  
DmPI31 Drosophila melanogaster proteasome inhibitor 31 
DNA Deoxyribonucleic acid 




DNA-BD  DNA-binding domain 
dNTP Deoxyribonucleotide triphosphate 
DTT  Dithiothreitol 
e.g. exempli gratia 
E1 Ubiquitin-activating enzyme 
E2  Ubiquitin-conjugating enzyme  
E3  Ubiquitin ligase enzyme  




Ethylene glycol tetraacetic acid 
EIF4G1 Eukaryotic translation initiation factor 4 gamma, 1 
En2-SA Mouse engrailed 2 gene splice acceptor 
ES  Embryonic stem 
FBP F-box protein 
FBXL  F-box protein with leucine-rich repeats 
FBXO  F-box protein with other domain motifs 
FBXW  F-box protein with WD40 domains 














Galactose-responsive transcription factor 4 
Gal4 DNA-activation domain 
Gal4 DNA-binding domain 
Glyceraldehyde 3-phosphate dehydrogenase 
GFAP  Glial fibrillary acidic protein  
GFP  Green fluorescent protein 
GST Glutathione S-transferase 
HBSS  Hank’s Balanced Salt Soulution  
HECT  Homologous to E6-AP carboxy terminal  
HEK293T  Human Embryonic Kidney 293T cells 
HEPES  4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 




HRP  Horseradish peroxidase 
HS  Horse serum 




Hepatoma up-regulated protein 
Isoleucine 
Immunoblot 
Iba1  Ionized calcium-binding adapter molecule 1 
ICC  Immunocytochemistry 
IgG Immunoglobulin G 
IHC  Immunohistochemistry 
IP  Immunoprecipitation 
















Light chain 1, 2 
Leucine 
Leucine-rich repeat kinase 2 







Mitochondrial aggregation and genome destruction 






mm2 Square millimeter 



















ns  non-significant 
NT N-terminus 
OD Optical density 
P(n) Postnatal Day (n) 
pA Polyadenylation 
PBS  Phosphate-buffered saline 
PBST  Phosphate-buffered saline with Triton-X 





PMSF  Phenylmethanesulfonylfluoride 
PPS  Parkinsonian-pyramidal syndrome 
PRR Proline-rich region 
PSG Penicillin/Streptomycin with L-Glutamine 








Proteasomal subunit alpha 2 
Proteasomal subunit beta 5 
PTEN Induced Putative Kinase 1 
Phosphatase and tensin homolog 
Arginine 
Rabbit 
RING-box protein 1 
RING  
RIPA 
Really Interesting New Gene 
Radioimmunoprecipitation assay buffer 
RNA Ribonucleic acid 
RNAi  RNA interference 
rpm Revolutions per minute 




Rpt6 RP triphosphatase 
RT  Room temperature 
s.e.m. Standard error of the mean 
SCF  Skp, Cullin, F-box-containing complex 
SDS  Sodium dodecyl sulfate 
SDS-PAGE  SDS-Polyacrylamide gel electrophoresis 
shRNA  Short hairpin RNA 
SKP1  
SNCA 
S-phase kinase-associated protein 1 
Synuclein, alpha (non A4 component of amyloid      
precursor) 
SNP  Single nucleotide polymorphism 




Tris base, Acetic acid and EDTA 




Tumor necrosis factor 
TNF receptor-associated factor 2 
TdT-mediated dUTP Nick-End Labeling 











Ubiquitin carboxyl-terminal esterase L1 
Ubiquitin-interacting motif 
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